

## Table of Contents

List of Tables.....	2
List of Figures .....	5
List of Boxes .....	6
List of Abbreviations and Acronyms.....	7
NARMS Working Group .....	8
What is New in the NARMS Report for 2009 .....	12
Introduction.....	13
WHO Categorization of Antimicrobial Agents .....	14
Summary of NARMS 2009 Surveillance Data .....	15
Antimicrobial Resistance: 1996–2009 .....	18
Surveillance and Laboratory Testing Methods .....	25
Results .....	32
1. Non-typhoidal <i>Salmonella</i> .....	32
A. <i>Salmonella</i> ser. Enteritidis .....	35
B. <i>Salmonella</i> ser. Typhimurium .....	37
C. <i>Salmonella</i> ser. Newport.....	39
D. <i>Salmonella</i> ser. Heidelberg .....	41
E. <i>Salmonella</i> ser. I 4,[5],12:i:- .....	43
2. Typhoidal <i>Salmonella</i> .....	48
3. <i>Shigella</i> .....	54
4. <i>Escherichia coli</i> O157 .....	61
5. <i>Campylobacter</i> .....	63
References .....	68
NARMS Publications in 2009.....	69
Appendix A.....	70
Summary of <i>Escherichia coli</i> Resistance Surveillance Pilot Study, 2009.....	70
<i>Escherichia coli</i> working group .....	70
Centers for Disease Control and Prevention.....	70

**Suggested Citation:** CDC. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2009. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2010.

**Information Available Online:** Previous reports and additional information about NARMS are posted on the CDC NARMS website: <http://www.cdc.gov/narms>

## List of Tables

Table 1.	WHO categorization of antimicrobials of critical importance to human medicine .....	14
Table 2.	Population size and number of isolates received and tested, NARMS, 2009.....	24
Table 3.	Antimicrobial agents used for susceptibility testing for <i>Salmonella</i> , <i>Shigella</i> , and <i>Escherichia coli</i> O157 isolates, NARMS, 2009 .....	26
Table 4.	Antimicrobial agents used for susceptibility testing of <i>Campylobacter</i> isolates, NARMS, 1997–2009 .....	28
Table 5.	Minimum inhibitory concentrations (MICs) and resistance of non-typhoidal <i>Salmonella</i> isolates to antimicrobial agents, 2009 (N=2192).....	32
Table 6.	Percentage and number of non-typhoidal <i>Salmonella</i> isolates resistant to antimicrobial agents, 2000–2009 .....	33
Table 7.	Resistance patterns of non-typhoidal <i>Salmonella</i> isolates, 2000–2009 .....	33
Table 8.	Twenty most common non-typhoidal <i>Salmonella</i> serotypes in NARMS, 2009 .....	34
Table 9.	Minimum inhibitory concentrations (MICs) and resistance of <i>Salmonella</i> ser. Enteritidis isolates to antimicrobial agents, 2009 (N=410).....	35
Table 10.	Percentage and number of <i>Salmonella</i> ser. Enteritidis isolates resistant to antimicrobial agents, 2000–2009 .....	36
Table 11.	Resistance patterns of <i>Salmonella</i> ser. Enteritidis isolates, 2000–2009.....	37
Table 12.	Minimum inhibitory concentrations (MICs) and resistance of <i>Salmonella</i> ser. Typhimurium isolates to antimicrobial agents, 2009 (N=371).....	37
Table 13.	Percentage and number of <i>Salmonella</i> ser. Typhimurium isolates resistant to antimicrobial agents, 2000–2009 .....	38
Table 14.	Resistance patterns of <i>Salmonella</i> ser. Typhimurium isolates, 2000–2009 .....	39
Table 15.	Minimum inhibitory concentrations (MICs) and resistance of <i>Salmonella</i> ser. Newport isolates to antimicrobial agents, 2009 (N=236).....	39
Table 16.	Percentage and number of <i>Salmonella</i> ser. Newport isolates resistant to antimicrobial agents, 2000–2009 .....	40
Table 17.	Resistance patterns of <i>Salmonella</i> ser. Newport isolates, 2000–2009.....	41
Table 18.	Minimum inhibitory concentrations (MICs) and resistance of <i>Salmonella</i> ser. Heidelberg isolates to antimicrobial agents, 2009 (N=86).....	41
Table 19.	Percentage and number of <i>Salmonella</i> ser. Heidelberg isolates resistant to antimicrobial agents, 2000–2009 .....	42
Table 20.	Resistance patterns of <i>Salmonella</i> ser. Heidelberg isolates, 2000–2009.....	43
Table 21.	Minimum inhibitory concentrations (MICs) and resistance of <i>Salmonella</i> ser. I 4,[5],12:i- isolates to antimicrobial agents, 2009 (N=72).....	43
Table 22.	Percentage and number of <i>Salmonella</i> ser. I 4,[5],12:i- isolates resistant to antimicrobial agents, 2000–2009 .....	44
Table 23.	Resistance patterns of <i>Salmonella</i> ser. I 4,[5],12:i- isolates, 2000–2009 .....	45
Table 24.	Number and percentage of isolates with resistance to at least ACSSuT, ACSSuTAuCx, nalidixic acid, and ceftriaxone among the 20 most common non-typhoidal <i>Salmonella</i> serotypes isolated in NARMS, 2009.....	46
Table 25.	Minimum inhibitory concentrations (MICs) and resistance of <i>Salmonella</i> ser. Typhi isolates to antimicrobial agents, 2009 (N=361) .....	48

Table 26. Percentage and number of <i>Salmonella</i> ser. Typhi isolates resistant to antimicrobial agents, 2000–2009.....	49
Table 27. Resistance patterns of <i>Salmonella</i> ser. Typhi isolates, 2000–2009.....	49
Table 28. Frequency of <i>Salmonella</i> ser. Paratyphi A, Paratyphi B, and Paratyphi C isolated in NARMS, 2009.....	50
Table 29. Minimum inhibitory concentrations (MICs) and resistance of <i>Salmonella</i> ser. Paratyphi A, Paratyphi B, and Paratyphi C isolates to antimicrobial agents, 2009 (N=102).....	50
Table 30. Percentage and number of <i>Salmonella</i> ser. Paratyphi A, Paratyphi B, and Paratyphi C isolates resistant to antimicrobial agents, 2000–2009.....	51
Table 31. Resistance patterns of <i>Salmonella</i> ser. Paratyphi A, Paratyphi B, and Paratyphi C isolates, 2000–2009.....	51
Table 32. Frequency of <i>Shigella</i> species isolated in NARMS, 2009.....	54
Table 33. Minimum inhibitory concentrations (MICs) and resistance of <i>Shigella</i> isolates to antimicrobial agents, 2009 (N=475).....	54
Table 34. Percentage and number of <i>Shigella</i> isolates resistant to antimicrobial agents, 2000–2009.....	55
Table 35. Resistance patterns of <i>Shigella</i> isolates, 2000–2009.....	56
Table 36. Minimum inhibitory concentrations (MICs) and resistance of <i>Shigella sonnei</i> isolates to antimicrobial agents, 2009 (N=410).....	56
Table 37. Percentage and number of <i>Shigella sonnei</i> isolates resistant to antimicrobial agents, 2000–2009.....	57
Table 38. Resistance patterns of <i>Shigella sonnei</i> isolates, 2000–2009.....	58
Table 39. Minimum inhibitory concentrations and resistance of <i>Shigella flexneri</i> isolates to antimicrobial agents, 2009 (N=57).....	58
Table 40. Percentage and number of <i>Shigella flexneri</i> isolates resistant to antimicrobial agents, 2000–2009.....	59
Table 41. Resistance patterns of <i>Shigella flexneri</i> isolates, 2000–2009.....	60
Table 42. Minimum inhibitory concentrations (MICs) and resistance of <i>Escherichia coli</i> O157 isolates to antimicrobial agents, 2009 (N=188).....	61
Table 43. Percentage and number of <i>Escherichia coli</i> O157 isolates resistant to antimicrobial agents, 2000–2009.....	62
Table 44. Resistance patterns of <i>Escherichia coli</i> O157 isolates, 2000–2009.....	62
Table 45. Frequency of <i>Campylobacter</i> species isolated in NARMS, 2009.....	63
Table 46. Minimum inhibition concentrations (MICs) and resistance of <i>Campylobacter</i> isolates to antimicrobial agents, 2009 (N=1502).....	63
Table 47. Percentage and number of <i>Campylobacter</i> isolates resistant to antimicrobial agents, 2000–2009.....	64
Table 48. Resistance patterns of <i>Campylobacter</i> isolates, 2000–2009.....	64
Table 49. Minimum inhibitory concentrations (MICs) and resistance of <i>Campylobacter jejuni</i> isolates to antimicrobial agents, 2009 (N=1355).....	65
Table 50. Percentage and number of <i>Campylobacter jejuni</i> isolates resistant to antimicrobial agents, 2000–2009.....	66
Table 51. Minimum inhibitory concentrations (MICs) and resistance of <i>Campylobacter coli</i> isolates to antimicrobial agents, 2009 (N=143).....	66
Table 52. Percentage and number of <i>Campylobacter coli</i> isolates resistant to antimicrobial agents, 2000–2009.....	67
Table 53. Antimicrobial agents used for susceptibility testing of <i>Escherichia coli</i> , 2009.....	72

<b>Table 54. Minimum inhibition concentrations (MICs) and resistance of <i>Escherichia coli</i> isolates to antimicrobial agents, 2009 (N=45) .....</b>	<b>72</b>
<b>Table 55. Percentage and number of <i>Escherichia coli</i> isolates resistant to antimicrobial agents, 2004–2009.....</b>	<b>73</b>
<b>Table 56. Resistance patterns of <i>Escherichia coli</i> isolates, 2004–2009 .....</b>	<b>74</b>

## List of Figures

Figure 1. Percentage of non-typhoidal <i>Salmonella</i> isolates resistant to nalidixic acid, by year, 1996–2009 .....	18
Figure 2. Percentage of non-typhoidal <i>Salmonella</i> isolates resistant to ceftriaxone, by year, 1996–2009 .....	19
Figure 3. Percentage of <i>Salmonella</i> ser. Enteritidis isolates resistant to nalidixic acid, by year, 1996–2000 .....	19
Figure 4. Percentage of <i>Salmonella</i> ser. Heidelberg isolates resistant to ceftriaxone, by year, 1996–2009 .....	20
Figure 5. Percentage of <i>Salmonella</i> ser. Typhimurium isolates resistant to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline (ACSSuT), by year, 1996–2009 .....	20
Figure 6. Percentage of <i>Salmonella</i> ser. Newport isolates resistant to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftriaxone (ACSSuTAuCx), by year, 1996–2009 .....	21
Figure 7. Percentage of non-typhoidal <i>Salmonella</i> isolates resistant to 1 or more antimicrobial classes, by year, 1996–2009 .....	21
Figure 8. Percentage of non-typhoidal <i>Salmonella</i> isolates resistant to 3 or more antimicrobial classes, by year, 1996–2009 .....	22
Figure 9. Percentage of <i>Salmonella</i> ser. Typhi isolates resistant to nalidixic acid, by year, 2000–2009 ..	22
Figure 10. Percentage of <i>Campylobacter</i> isolates resistant to ciprofloxacin, by year, 1997–2009 .....	23
Figure 11. How to read a squashtogram .....	30
Figure 12. Proportional chart, a categorical graph of a squashtogram .....	31
Figure 13. Antimicrobial resistance pattern for non-typhoidal <i>Salmonella</i> , 2009 .....	32
Figure 14. Antimicrobial resistance pattern for <i>Salmonella</i> ser. Enteritidis, 2009 .....	35
Figure 15. Antimicrobial resistance pattern for <i>Salmonella</i> ser. Typhimurium, 2009 .....	38
Figure 16. Antimicrobial resistance pattern for <i>Salmonella</i> ser. Newport, 2009 .....	40
Figure 17. Antimicrobial resistance pattern for <i>Salmonella</i> ser. Heidelberg, 2009 .....	42
Figure 18. Antimicrobial resistance pattern for <i>Salmonella</i> ser. I 4,[5],12:i:-, 2009 .....	44
Figure 19. Antimicrobial resistance pattern for <i>Salmonella</i> ser. Typhi, 2009 .....	48
Figure 20. Antimicrobial resistance pattern for <i>Salmonella</i> ser. Paratyphi A, Paratyphi B, and Paratyphi C, 2009 .....	50
Figure 21. Antimicrobial resistance pattern for <i>Shigella</i> , 2009 .....	55
Figure 22. Antimicrobial resistance pattern for <i>Shigella sonnei</i> , 2009 .....	57
Figure 23. Antimicrobial resistance pattern for <i>Shigella flexneri</i> , 2009 .....	59
Figure 24. Antimicrobial resistance pattern for <i>Escherichia coli</i> O157, 2009 .....	61
Figure 25. Antimicrobial resistance pattern for <i>Campylobacter</i> , 2009 .....	63
Figure 26. Antimicrobial resistance pattern for <i>Campylobacter jejuni</i> , 2009 .....	65
Figure 27. Antimicrobial resistance pattern for <i>Campylobacter coli</i> , 2009 .....	67
Figure 28. Antibiotic resistance pattern for <i>Escherichia coli</i> , 2009 .....	73

## List of Boxes

<b>Box 1. Changes in antimicrobial resistance: 2009 vs. 2003–07</b> .....	<b>17</b>
<b>Box 2. Four major multidrug-resistant patterns among non-typhoidal <i>Salmonella</i> isolates, 1996–2009 ...</b>	<b>47</b>
<b>Box 3. Molecular characterization of non-Typhi <i>Salmonella enterica</i> that show decreased susceptibility to extended-spectrum cephalosporins</b> .....	<b>52</b>
<b>Box 4. Reduced azithromycin susceptibility in <i>Shigella sonnei</i>, United States</b> .....	<b>53</b>

## List of Abbreviations and Acronyms

ACSSuT	Resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, and tetracycline
ACSSuTAuCx	Resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, amoxicillin-clavulanic acid, and ceftriaxone
ACT/S	Resistance to at least ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole
ANT/S	Resistance to at least ampicillin, nalidixic acid and trimethoprim-sulfamethoxazole
AT/S	Resistance to at least ampicillin and trimethoprim-sulfamethoxazole
CDC	Centers for Disease Control and Prevention
CI	Confidence interval
CLSI	Clinical and Laboratory Standards Institute
EIP	Emerging Infections Program
ELC	Epidemiology and Laboratory Capacity
FDA-CVM	Food and Drug Administration-Center for Veterinary Medicine
FoodNet	Foodborne Diseases Active Surveillance Network
MIC	Minimum inhibitory concentration
NARMS	National Antimicrobial Resistance Monitoring System for Enteric Bacteria
OR	Odds ratio
PHLIS	Public Health Laboratory Information System
USDA	United States Department of Agriculture
WHO	World Health Organization

## NARMS Working Group

### **Centers for Disease Control and Prevention**

#### *Enteric Diseases Epidemiology Branch*

#### *Enteric Diseases Laboratory Branch*

#### *Division of Foodborne, Waterborne and Environmental Diseases*

#### *National Center for Emerging and Zoonotic Infectious Diseases*

Olympia Anderson  
Frederick Angulo  
Ezra Barzilay  
Jason Folster  
Peter Gerner-Smidt  
Audrey Green  
Patricia Griffin  
Robert Michael Hoekstra  
Rebecca Howie  
Kevin Joyce  
Maria Karlsson  
Beth Karp  
Amy Krueger  
Kathryn Lupoli  
Andre McCullough  
Felicita Medalla  
Gary Pecic  
Jared Reynolds  
Regan Rickert  
Jacinta Smith  
Andrew Stuart  
Robert Tauxe  
Jean Whichard

### **U.S. Food and Drug Administration**

#### *Center for Veterinary Medicine*

Heather Green  
Claudine Kabera  
Patrick McDermott  
Emily Tong  
Niketia Womack

### **Participating State and Local Health Departments**

#### *Alabama Department of Public Health*

LaDonna Cranidiotis  
Sherri Davidson  
Sharon Massingale  
Patricia Morrow  
Joanna Roberson

#### *Alaska Department of Health and Social Services*

Shellie Smith  
Catherine Xavier

#### *Arizona Department of Health Services*

Shoana Anderson  
Aarikha D'Souza  
Daniel Flood  
Melissa Hoffman  
Ken Komatsu  
William Slanta  
Victor Waddell

#### *Arkansas Department of Health*

Rossina Stefanova

#### *California Department of Health Services*

Wendy Cheung  
Claudia Crandall  
Samar Fontanoz  
Paul Kimsey  
Will Probert  
Sam Shin  
Duc Vugia

#### *Colorado Department of Public Health and Environment*

Alicia Cronquist  
Laura Gillim-Ross  
Joyce Knutsen  
Hugh Maguire

#### *Connecticut Department of Public Health*

Diane Barden  
Sharon Hurd  
Aristea Kinney  
Mona Mandour

#### *Delaware Health and Social Services*

Gaile McLaughlin  
Bela Patel  
Debra Rutledge

#### *Florida Department of Health*

Ronald Baker  
Maria Calcaterra  
Sonia Etheridge  
Dian Sharma

#### *Georgia Division of Public Health*

Jim Benson  
Elizabeth Franko  
Tameka Hayes  
Mary Hodel  
Susan Lance  
Bob Manning  
Mahin Park  
Lynett Poventud  
Suzanne Segler  
Stepy Thomas  
Melissa Tobin-D'Angelo

#### *Hawaii Department of Health*

Rebecca Kanenaka  
Norman O'Connor

#### *Houston Health and Human Services Department*

Raouf Arafat  
Adebowale Awosika-Olumo  
Gregory Dufour  
Vern Juchau  
Sudha Pottumarthy  
Joan Rogers

#### *Idaho Department of Health and Welfare*

Colleen Greenwalt  
Vivian Lockary  
Raemi Nolevanko

#### *Illinois Department of Public Health*

Nancy Barstead  
Bob Cox  
Mark Dworkin  
Juan Garcia  
Rebecca Hambelton  
Stephen Hendren  
Steve Hopkins  
Patrick Miller  
Mohammad Nasir  
Kiran Patel  
Tricia Patterson  
Guinevere Reserva  
Bindu Shah  
Andrea Stadsholt

*Indiana State Department of Health*

Brent Barrett  
Amie May  
John Radosevic

*Iowa Department of Public Health, University Hygienic Laboratory*

Mary DeMartino  
Randy Groepper

*Kansas Department of Health and Environment*

Cheryl Banez-Ocfemia  
Robert Flahart  
Gail Hansen  
Carissa Pursell  
June Sexton  
Kathleen Waters

*Kentucky Department of Public Health*

Robin Cotton  
Karim George  
William Grooms  
Darrin Sevier  
Jack Wiedo

*Los Angeles County Department of Health Services*

Michael Stephens  
Sheena Chu  
Sue Sabet  
Laurene Mascola  
Roshan Reporter  
Joan Sturgeon

*Louisiana Department of Health and Hospitals*

Gary Balsamo  
Erin Delaune  
Wayne Dupree  
Catrin Jones-Nazar  
Lori Kravet  
Steven Martin  
Raoult Ratard  
Theresa Sokol  
Susanne Straif-Bourgeois

*Maine Department of Human Services*

Geoff Beckett  
Kathleen Gensheimer  
Jeff Randolph  
Vicki Rea  
Lori Webber  
Donna Wrigley  
Anthony Yartel

*Maryland Department of Health and Mental Hygiene*

David Blythe  
Kirsten Larson  
Celere Leonard  
Amanda Palmer  
Jafar Razeq  
Pat Ryan

*Massachusetts Department of Public Health*

Catherine Brown  
Alfred DeMaria  
Robert Goldbaum  
Emily Harvey  
Patricia Kludt  
Joseph Peppe  
Tracy Stiles

*Michigan Department of Community Health*

Carrie Anglewicz  
Frances Downes  
Teri Lee Dyke  
James Rudrik  
William Schneider  
Patricia Somsel

*Minnesota Department of Health*

John Besser  
Billie Juni  
Fe Leano  
Stephanie Meyer  
Kirk Smith  
Charlott Taylor  
Theresa Weber

*Mississippi Department of Health*

Jannifer Anderson  
Jane Campbell  
Gloria Kendrick  
Sheryl Hand  
Cathie Hoover  
Daphne Ware

*Missouri Department of Health*

David Byrd  
Steve Gladbach  
Jason Herstein  
Harvey Marx  
JoAnn Rudroff

*Montana Department of Public Health and Human Services*

Bonnie Barnard  
Anne Weber  
Susanne Zanto

*Nebraska Health and Human Services and the Nebraska Public Health Laboratory*

Amy Armbrust  
Jude Dean  
Paul Fey  
Peter Iwen  
Tom Safranek

*Nevada Department of Health and Human Services*

Vince Abitria  
Patricia Armour  
Stephanie Ernaga  
Jaime Frank  
Paul Hug  
Bradford Lee  
Susanne Quianzon  
Lisa Southern  
Stephanie Van Hooser

*New Hampshire Department of Health and Human Services*

Christine Adamski  
Christine Bean  
Elizabeth Daly  
Wendy Lamothe  
Nancy Taylor  
Daniel Tullo

*New Jersey Department of Health*

Ruth Besco  
Michelle Malavet  
Sylvia Matiuck  
Paul Seitz

*New Mexico Department of Health*

Lisa Butler  
Cynthia Nicholson  
Lisa Onischuk  
Erica Pierce  
Paul Torres

*New York City Department of Health*

Sharon Balter  
Ludwin Chicaiza  
Heather Hanson  
Lillian Lee  
Jennifer Rakeman  
Vasudha Reddy

*New York State Department of Health*

Leeanna Armstrong  
Nellie Dumas  
Tammy Quinlan  
Dale Morse  
Tim Root  
Shelley Zansky

*North Carolina Department of Health and Human Services*

Denise Griffin  
Debra Springer

*North Dakota Department of Health*

Lisa Elijah  
Julie Wagendorf  
Eric Hieb  
Nicole Meier  
Tracy Miller  
Lisa Well

*Ohio Department of Health*

Rick Bokanyi  
Tammy Bannerman  
Jane Carmean  
Larry King  
Mary Kay Parrish  
Susan Luning  
Ellen Salehi

*Oklahoma State Department of Health*

Rebekah Berry  
Mike Lytle  
Mike McDermot

*Oregon Department of Human Service*

Debbie Berquist  
Cathy Ciaffoni  
Paul Cieslak  
Dawn Daly  
Emilio Debess  
Julie Hatch  
Beletsachew Shiferaw  
Larry Stauffer  
Janie Tierheimer  
Robert Vega  
Veronica Williams

*Pennsylvania Department of Human Service*

Wayne Chmielecki  
Lisa Dettinger  
Nkuchia Mikanatha  
Stanley Reynolds  
Carol Sandt  
James Tait

*Rhode Island Department of Health*

Tara Cooper  
Deanna Simmons  
Cindy Vanner

*South Carolina Department of Health and Environmental Control*

Dana Giurgiutiu  
Mamie Turner  
Jennifer Meredith  
Arthur Wozniak

*South Dakota Department of Health*

Christopher Carlson  
Lon Kightlinger  
Mike Smith  
Yvette Thomas

*Tennessee Department of Health*

Parvin Arjmandi  
Paula Bailey  
John Dunn  
Samir Hanna  
Henrietta Hardin

*Texas Department of State Health Services*

Tamara Baldwin  
Leslie Bullion  
Elizabeth Delamater  
Linda Gaul  
Eldridge Hutcheson  
Miriam Johnson  
Susan Neill  
Pushker Raj  
Ana Valle

*Utah Department of Health*

Dan Andrews  
Kim Christensen  
Jana Coombs  
Cindy Fisher  
David Jackson  
Barbara Jepson  
Susan Mottice

*Vermont Department of Health*

Erica Berl  
Valerie Cook  
Eunice H. Froeliger  
Christine LaBarre

*Virginia Division of Consolidated Laboratory Services and Virginia Department of Health*

Ellen Basinger  
Sherry Giese  
Jody Lowman  
Mary Mismas  
Denise Toney

*Washington Department of Health*

Jennifer Breezee  
Romesh Gautom  
Donna Green  
Brian Hiatt  
Yolanda Houze  
Kathryn MacDonald

*West Virginia Department of Health and Human Resources*

Danae Bixler  
Christi Clark  
Maria del Rosario  
Loretta Haddy  
Andrea Labik  
Megan Young

*Wisconsin Department of Health and Family Services*

John Archer  
Susann Ahrabi-Fard  
Charles Brokopp  
Jeffrey Davis  
Rick Heffernan  
Rachel Klos  
Tim Monson  
Dave Warshauer

*Wyoming Department of Health*

Richard Harris

John Harrison

Clay Van Houten

Tracy Murphy

Jim Walford

### **Mutually exclusive criteria heading**

In Box 2 (page 47), we describe the 4 most common multidrug-resistant (MDR) patterns among non-typhoidal *Salmonella* isolates based on resistance to 7 of the 15 agents currently tested in NARMS: ampicillin (A), chloramphenicol (C), streptomycin (S), sulfonamide (Su), tetracycline (T), amoxicillin-clavulanic acid (Au), and ceftriaxone (Cx). Resistance to the 7 agents has been used in NARMS to categorize specific MDR patterns. Unlike MDR criteria used for tables in previous reports and other sections of this report, we used mutually exclusive criteria in the new section. Use of mutually exclusive criteria is important in monitoring major and emerging patterns, which may be driven by different resistance mechanisms.

### **Update of trimethoprim-sulfamethoxazole data for *Shigella***

Automated fluorescence-based methods have been used since 2001 to determine minimum inhibitory concentrations (MIC) for the drugs tested for *Enterobacteriaceae*. These automated fluorescence-based methods are designed to emulate MICs that would be obtained if the results were read visually. Recent laboratory comparison studies showed that the automated fluorescence-based method was not reproducibly emulating visually-determined results for trimethoprim-sulfamethoxazole with *Shigella* species. The test manufacturer has updated the automated fluorescence-based method to improve concordance with visual results, and these updates have been applied retroactively to the affected data in the database. This has resulted in lower MIC results and lower prevalence of trimethoprim-sulfamethoxazole resistance for *Shigella*.

## Introduction

The National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria is a collaboration among the Centers for Disease Control and Prevention (CDC), [U.S. Food and Drug Administration's Center for Veterinary Medicine](#) (FDA-CVM), and [U.S. Department of Agriculture](#) (USDA). The primary purpose of NARMS at CDC is to monitor antimicrobial resistance among enteric bacteria isolated from humans. Other components of the interagency NARMS program include surveillance for resistance in enteric bacteria isolated from foods, conducted by the FDA-CVM (<http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMonitoringSystem/default.htm>), and resistance in enteric bacteria isolated from animals, conducted by the USDA Agricultural Research Service ([http://www.ars.usda.gov/main/site\\_main.htm?modecode=66-12-05-08](http://www.ars.usda.gov/main/site_main.htm?modecode=66-12-05-08)).

Many NARMS activities are conducted within the framework of CDC's Emerging Infections Program (EIP), Epidemiology and Laboratory Capacity (ELC) Program, and the Foodborne Diseases Active Surveillance Network (FoodNet). In addition to surveillance of resistance in enteric pathogens, the NARMS program at CDC also includes public health research into the mechanisms of resistance, education efforts to promote prudent use of antimicrobial agents, and studies of resistance in commensal organisms.

Before NARMS was established, CDC monitored antimicrobial resistance in *Salmonella*, *Shigella*, and *Campylobacter* through periodic surveys of isolates from a panel of sentinel counties. NARMS at CDC began in 1996 with prospective monitoring of antimicrobial resistance among clinical non-typhoidal *Salmonella* and *Escherichia coli* O157 isolates in 14 sites. In 1997, testing of clinical *Campylobacter* isolates was initiated in the five sites participating in FoodNet. Testing of clinical *Salmonella enterica* serotype Typhi and *Shigella* isolates was added in 1999. Since 2003, all 50 states have been forwarding a representative sample of non-typhoidal *Salmonella*, *Salmonella* ser. Typhi, *Shigella*, and *E. coli* O157 isolates to NARMS for antimicrobial susceptibility testing, and 10 FoodNet states have been participating in *Campylobacter* surveillance. Since 2008, all 50 states have been forwarding every *Salmonella* Paratyphi A and C to NARMS for antimicrobial susceptibility testing.

This annual report includes CDC's surveillance data for 2009 for non-typhoidal *Salmonella*, typhoidal *Salmonella*, *Shigella*, *Campylobacter* and *E. coli* O157 isolates. Data for earlier years are presented in tables and graphs when appropriate. Antimicrobial classes defined by Clinical and Laboratory Standards Institute (CLSI) are used in data presentation and analysis. CLSI classes constitute major classifications of antimicrobial agents, e.g., aminoglycosides and cepheems.

This report also includes the World Health Organization's categorization of antimicrobials of critical importance to human medicine ([Table 1](#)). The table includes only antimicrobials that are tested in NARMS.

Additional NARMS data and more information about NARMS activities are available at <http://www.cdc.gov/narms>

## WHO Categorization of Antimicrobial Agents

In 2007, the World Health Organization (WHO) convened for the second time a panel of experts to develop a list of essential antimicrobial agents according to their importance to human medicine (WHO, 2007). The participants categorized antimicrobial agents as either Critically Important, Highly Important, or Important based upon two criteria: (1) sole therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire resistance genes from non-human sources. Antimicrobial agents tested in NARMS have been included in the WHO categorization table.

- Antimicrobial agents are critically important if both criteria (1) and (2) are true.
- Antimicrobial agents are highly important if either criterion (1) or (2) is true.
- Antimicrobial agents are important if neither criterion is true.

**Table 1. WHO categorization of antimicrobials of critical importance to human medicine**

WHO Category Level	Importance	CLSI Class	Antimicrobial Agent tested in NARMS
<b>I</b>	<b>Critically important</b>	Aminoglycosides	Amikacin
			Gentamicin
			Streptomycin
		$\beta$ -lactam / $\beta$ -lactamase inhibitor combinations	Amoxicillin-clavulanic acid
		Cephems	Ceftriaxone
		Ketolides	Telithromycin
		Macrolides	Azithromycin
			Erythromycin
		Penicillins	Ampicillin
Quinolones	Ciprofloxacin		
	Nalidixic acid		
<b>II</b>	<b>Highly important</b>	Aminoglycosides	Kanamycin
		Cephems	Cefoxitin
			Cephalothin
		Folate pathway inhibitors	Sulfamethoxazole / Sulfisoxazole
			Trimethoprim-sulfamethoxazole
		Phenicols	Chloramphenicol
Tetracyclines*	Tetracycline		
<b>III</b>	<b>Important</b>	Lincosamides	Clindamycin

\*In 2010, WHO recategorized tetracycline from highly important to critically important. The NARMS 2010 annual report will reflect this change.

## Summary of NARMS 2009 Surveillance Data

### Population

In 2009, all 50 states participated in NARMS, representing the entire U.S. population of approximately 307 million persons ([Table 2](#)). Surveillance was conducted in all states for non-typhoidal *Salmonella*, typhoidal *Salmonella*, *Shigella*, and *Escherichia coli* O157. For *Campylobacter*, surveillance was conducted in 10 states that comprise the Foodborne Diseases Active Surveillance Network (FoodNet), representing approximately 47 million persons (15% of the U.S. population).

### Clinically Important Antimicrobial Resistance Patterns

In the United States, fluoroquinolones (e.g., ciprofloxacin) and third-generation cephalosporins (e.g., ceftriaxone) are commonly used to treat severe *Salmonella* infections, including *Salmonella* ser. Typhi, the organism that causes typhoid fever. In *Enterobacteriaceae*, resistance to nalidixic acid, an elementary quinolone, correlates with decreased susceptibility to ciprofloxacin (MIC  $\geq 0.12$   $\mu\text{g/mL}$ ) and possible fluoroquinolone treatment failure. A substantial proportion of *Enterobacteriaceae* isolates tested in 2009 demonstrated resistance to these clinically important antimicrobial agents.

Among non-typhoidal *Salmonella* isolates:

- 1.8% (39/2192) were resistant to nalidixic acid. The most common serotypes among the nalidixic acid-resistant isolates were Enteritidis (15/39, 38%) and Typhimurium (8/39, 21%)
  - 3.7% (15/410) of *Salmonella* ser. Enteritidis isolates were nalidixic acid resistant
  - 2.2% (8/371) of *Salmonella* ser. Typhimurium isolates were nalidixic acid resistant
- 3.4% (75/2192) were resistant to ceftriaxone. The most common serotypes among the ceftriaxone resistant isolates were Typhimurium (24/75, 32%) and Heidelberg (18/75, 24%)
  - 21% (18/86) of *Salmonella* ser. Heidelberg isolates were ceftriaxone resistant
  - 6.5% (24/371) of *Salmonella* ser. Typhimurium isolates were ceftriaxone resistant

Among *Salmonella* ser. Typhi isolates:

- 60% (217/361) were resistant to nalidixic acid and 3.3% (12/361) to ciprofloxacin

Among *Shigella* isolates:

- 2.1% (10/475) were resistant to nalidixic acid and 0.6% (3/475) to ciprofloxacin

In *Campylobacter*, fluoroquinolones and macrolides (e.g., erythromycin) are important agents in the treatment of severe infections. Among *Campylobacter* isolates:

- 23% (344/1502) were ciprofloxacin resistant, including
  - 23% (312/1355) of *Campylobacter jejuni* isolates
  - 22% (31/143) of *Campylobacter coli* isolates
- 1.7% (25/1502) were erythromycin resistant, including
  - 1.5% (21/1355) *Campylobacter jejuni* isolates
  - 2.8% (4/143) of *Campylobacter coli* isolates

### Multidrug Resistance

Multidrug resistance is described in NARMS as resistance to three or more CLSI antimicrobial classes. Antimicrobial classes of agents defined by the Clinical and Laboratory Standards Institute (CLSI) are used in this report ([Table 3](#), [Table 4](#)). For non-typhoidal *Salmonella*, an important multidrug-resistant phenotype includes resistance to at least ampicillin, chloramphenicol, streptomycin, sulfonamide (sulfamethoxazole or sulfisoxazole), and tetracycline (ACSSuT). The ACSSuT phenotype includes resistance to at least five CLSI classes. Another important phenotype includes resistance to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftriaxone (ACSSuTAuCx). The ACSSuTAuCx phenotype includes resistance to at least 7 CLSI classes.

Among non-typhoidal *Salmonella* isolates:

- 13% (284/2192) were resistant to two or more CLSI classes of agents, 9.5% (209/2192) to three or more CLSI classes. Of the 209 isolates resistant to three or more CLSI classes, 50% were ser. Typhimurium. The serotypes with the highest proportion of isolates resistant to three or more CLSI classes were
  - Typhimurium (28%, 104/371), Heidelberg (26%, 22/86), and Newport (7.6%, 18/236)
- 5.1% (112/2192) were at least ACSSuT resistant. The serotypes with the highest proportion of isolates resistant to this phenotype were
  - Typhimurium (19%, 72/371) and Newport (6.4%, 15/236)
- 1.4% (30/2192) were at least ACSSuTAuCx resistant. The serotypes with the highest proportion of isolates resistant to this phenotype were
  - Newport (6.4%, 15/236) and Typhimurium (1.6%, 6/371)

Additional isolates resistant to three or more CLSI classes include

- 13% (46/361) of *Salmonella* ser. Typhi isolates
- 36% (173/475) of *Shigella* isolates
- 5.9% (11/188) of *E. coli* O157 isolates

## Box 1. Changes in antimicrobial resistance: 2009 vs. 2003–07

To understand changes in prevalence of antimicrobial resistance over time, we used logistic regression to compare the prevalence of specific antimicrobial resistance patterns among *Salmonella* and *Campylobacter* isolates tested in 2009 with the reference, which was the average prevalence of resistance in 2003–07. Since 2003, all 50 states have participated in *Salmonella* surveillance and all 10 FoodNet sites in *Campylobacter* surveillance. A description of the methods is included in this report (refer to Surveillance and Laboratory Testing Methods).

The differences between the prevalence of resistance in 2009 and the average prevalence of resistance in 2003–07 (Figure 1) were statistically significant for the following:


- Resistance to one or more CLSI classes in non-typhoidal *Salmonella* (NTS), lower in 2009 (17%) than in 2003–07 (20%) (OR=0.8, 95% CI [0.7–0.9])
- Resistance to three or more CLSI classes in NTS, lower in 2009 (9.5%) than in 2003–07 (12%) (OR=0.8, 95% CI [0.7–0.9])
- ACSSuTAuCx resistance in *Salmonella enterica* ser. Newport, lower in 2009 (6.4%) than in 2003–07 (13%) (OR=0.5, 95% CI [0.3–1.0])
- Nalidixic acid resistance in *Salmonella enterica* ser. Typhi, higher in 2009 (60%) than in 2003–07 (49%) (OR=1.6, 95% CI [1.2–2.0])

Ceftriaxone resistance in *Salmonella* ser. Heidelberg was higher in 2009 (21%) than the average prevalence of resistance in 2003–07 (7.9%) (OR=3.5, 95% CI [1.8, 6.7]) (Figure 1). The data indicate that increased resistance was mainly driven by California and Washington. Trend analysis excluding California and Washington shows no significant change (OR=1.4, 95% CI [0.6, 3.6]). Thus, the reported OR represents a summary of unequal trends among sites.

The differences between the prevalence of resistance in 2009 and the average prevalence of resistance in 2003–07 (Figure 1) were not statistically significant for the following:

- Nalidixic acid resistance in NTS (OR=0.9, 95% CI [0.6–1.2])
- Ceftriaxone resistance in NTS (OR=1.0, 95% CI [0.8–1.3])
- Nalidixic acid resistance in *Salmonella enterica* ser. Enteritidis (OR=0.7, 95% CI [0.4–1.1])
- ACSSuT resistance in *Salmonella enterica* ser. Typhimurium (OR=0.8, 95% CI [0.6–1.1])
- Ciprofloxacin resistance in *Campylobacter* (OR=1.1, 95% CI [1.0–1.3])
- Ciprofloxacin resistance in *Campylobacter jejuni* (OR=1.1, 95% CI [1.0–1.4])

**Figure 1. Summary of trend analysis of the prevalence of specific resistance patterns among *Salmonella* and *Campylobacter* isolates, 2009 compared with 2003–2007\***



\*The reference is the average prevalence of resistance in 2003–07. Logistic regression models adjusted for site. The odds ratios (ORs) and 95% confidence intervals (CIs) for 2009 compared with the reference were calculated using unconditional maximum likelihood estimation. ORs that do not include 1.0 in the 95% CIs are reported as statistically significant.

<sup>†</sup>Antimicrobial classes of agents defined by the Clinical and Laboratory Standards Institute (CLSI) are used.

<sup>‡</sup>Descriptive analysis suggests that increased resistance in 2009 was mainly driven by California and Washington. Thus, the reported OR represents a summary of unequal trends across sites.


<sup>§</sup>ACSSuTAuCx: resistance to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftriaxone.

<sup>¶</sup>ACSSuT: resistance to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline.

## Antimicrobial Resistance: 1996–2009

The following figures display resistance from 1996–2009 for non-typhoidal *Salmonella*, 2000–2009 for *Salmonella* ser. Typhi, and 1997–2009 for *Campylobacter*.

Figure 1. Percentage of non-typhoidal *Salmonella* isolates resistant to nalidixic acid, by year, 1996–2009



- --- Upper and lower limits of the individual 95% confidence intervals for annual percent resistant
- — Annual percent resistant

Figure 2. Percentage of *non-typhoidal Salmonella* isolates resistant to ceftriaxone, by year, 1996–2009




Figure 3. Percentage of *Salmonella ser. Enteritidis* isolates resistant to nalidixic acid, by year, 1996–2009




Figure 4. Percentage of *Salmonella ser. Heidelberg* isolates resistant to ceftriaxone, by year, 1996–2009





Figure 5. Percentage of *Salmonella ser. Typhimurium* isolates resistant to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline (ACSSuT), by year, 1996–2009



■ --- Upper and lower limits of the individual 95% confidence intervals for annual percent resistant  
 ● — Annual percent resistant

Figure 6. Percentage of *Salmonella ser. Newport* isolates resistant to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftriaxone (ACSSuTAuCx), by year, 1996–2009




Figure 7. Percentage of non-typhoidal *Salmonella* isolates resistant to 1 or more antimicrobial classes, by year, 1996–2009




Figure 8. Percentage of *non-typhoidal Salmonella* isolates resistant to 3 or more antimicrobial classes, by year, 1996–2009




Figure 9. Percentage of *Salmonella ser. Typhi* isolates resistant to nalidixic acid, by year, 2000–2009





Figure 10. Percentage of *Campylobacter* isolates resistant to ciprofloxacin, by year, 1997–2009



**Table 2. Population size and number of isolates received and tested, NARMS, 2009**

State/Site	Population Size	Non-typhoidal <i>Salmonella</i>		Typhoidal <i>Salmonella</i>		<i>Shigella</i>		<i>E. coli</i> O157		<i>Campylobacter</i> <sup>‡</sup>	
		n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Alabama	4,708,708	65	(3.0%)	2	(0.4%)	9	(1.9%)	2	(1.1%)		
Alaska	698,473	4	(0.2%)	0	(0.0%)	1	(0.2%)	0	(0.0%)		
Arizona	6,595,778	56	(2.6%)	4	(0.9%)	27	(5.7%)	2	(1.1%)		
Arkansas	2,889,450	23	(1.0%)	0	(0.0%)	9	(1.9%)	2	(1.1%)		
California <sup>§</sup>	27,113,653	184	(8.4%)	57	(12.3%)	2	(0.4%)	5	(2.7%)	76	(5.1%)
Colorado	5,024,748	34	(1.6%)	12	(2.6%)	6	(1.3%)	7	(3.7%)	57	(3.8%)
Connecticut	3,518,288	25	(1.1%)	5	(1.1%)	1	(0.2%)	4	(2.1%)	123	(8.2%)
Delaware	885,122	8	(0.4%)	0	(0.0%)	7	(1.5%)	0	(0.0%)		
District of Columbia	599,657	37	(1.7%)	3	(0.6%)	0	(0.0%)	0	(0.0%)		
Florida	18,537,969	17	(0.8%)	28	(6.0%)	0	(0.0%)	0	(0.0%)		
Georgia	9,829,211	133	(6.1%)	12	(2.6%)	29	(6.1%)	14	(7.4%)	473	(31.5%)
Hawaii	1,295,178	16	(0.7%)	6	(1.3%)	3	(0.6%)	1	(0.5%)		
Houston, Texas <sup>¶</sup>	2,257,926	34	(1.6%)	8	(1.7%)	8	(1.7%)	0	(0.0%)		
Idaho	1,545,801	8	(0.4%)	2	(0.4%)	1	(0.2%)	2	(1.1%)		
Illinois	12,910,409	78	(3.6%)	15	(3.2%)	30	(6.3%)	17	(9.0%)		
Indiana	6,423,113	31	(1.4%)	4	(0.9%)	1	(0.2%)	2	(1.1%)		
Iowa	3,007,856	17	(0.8%)	0	(0.0%)	4	(0.8%)	4	(2.1%)		
Kansas	2,818,747	14	(0.6%)	0	(0.0%)	9	(1.9%)	1	(0.5%)		
Kentucky	4,314,113	21	(1.0%)	0	(0.0%)	4	(0.8%)	0	(0.0%)		
Los Angeles <sup>**</sup>	9,848,011	63	(2.9%)	6	(1.3%)	2	(0.4%)	0	(0.0%)		
Louisiana	4,492,076	30	(1.4%)	0	(0.0%)	0	(0.0%)	0	(0.0%)		
Maine	1,318,301	1	(0.0%)	0	(0.0%)	0	(0.0%)	0	(0.0%)		
Maryland	5,699,478	60	(2.7%)	18	(3.9%)	17	(3.6%)	24	(12.8%)	186	(12.4%)
Massachusetts	6,593,587	58	(2.6%)	16	(3.5%)	11	(2.3%)	4	(2.1%)		
Michigan	9,969,727	42	(1.9%)	15	(3.2%)	8	(1.7%)	2	(1.1%)		
Minnesota	5,266,214	28	(1.3%)	5	(1.1%)	4	(0.8%)	8	(4.3%)	166	(11.1%)
Mississippi	2,951,996	37	(1.7%)	1	(0.2%)	4	(0.8%)	0	(0.0%)		
Missouri	5,987,580	38	(1.7%)	1	(0.2%)	35	(7.4%)	6	(3.2%)		
Montana	974,989	7	(0.3%)	1	(0.2%)	1	(0.2%)	2	(1.1%)		
Nebraska	1,796,619	10	(0.5%)	0	(0.0%)	8	(1.7%)	3	(1.6%)		
Nevada	2,643,085	12	(0.5%)	3	(0.6%)	3	(0.6%)	1	(0.5%)		
New Hampshire	1,324,575	10	(0.5%)	0	(0.0%)	2	(0.4%)	2	(1.1%)		
New Jersey	8,707,739	57	(2.6%)	44	(9.5%)	15	(3.2%)	7	(3.7%)		
New Mexico	2,009,671	10	(0.5%)	1	(0.2%)	4	(0.8%)	2	(1.1%)	142	(9.5%)
New York <sup>††</sup>	11,149,572	76	(3.5%)	19	(4.1%)	7	(1.5%)	6	(3.2%)	125	(8.3%)
New York City <sup>†††</sup>	8,391,881	74	(3.4%)	55	(11.9%)	18	(3.8%)	2	(1.1%)		
North Carolina	9,380,884	85	(3.9%)	11	(2.4%)	5	(1.1%)	2	(1.1%)		
North Dakota	646,844	6	(0.3%)	0	(0.0%)	2	(0.4%)	1	(0.5%)		
Ohio	11,542,645	81	(3.7%)	13	(2.8%)	20	(4.2%)	5	(2.7%)		
Oklahoma	3,687,050	34	(1.6%)	2	(0.4%)	12	(2.5%)	1	(0.5%)		
Oregon	3,825,657	26	(1.2%)	2	(0.4%)	3	(0.6%)	4	(2.1%)	113	(7.5%)
Pennsylvania	12,604,767	82	(3.7%)	22	(4.8%)	59	(12.4%)	1	(0.5%)		
Rhode Island	1,053,209	8	(0.4%)	1	(0.2%)	2	(0.4%)	1	(0.5%)		
South Carolina	4,561,242	58	(2.6%)	1	(0.2%)	4	(0.8%)	1	(0.5%)		
South Dakota	812,383	10	(0.5%)	2	(0.4%)	1	(0.2%)	3	(1.6%)		
Tennessee	6,296,254	41	(1.9%)	4	(0.9%)	16	(3.4%)	7	(3.7%)	41	(2.7%)
Texas <sup>§§</sup>	22,524,376	137	(6.3%)	16	(3.5%)	12	(2.5%)	2	(1.1%)		
Utah	2,784,572	23	(1.0%)	0	(0.0%)	1	(0.2%)	4	(2.1%)		
Vermont	621,760	1	(0.0%)	0	(0.0%)	0	(0.0%)	0	(0.0%)		
Virginia	7,882,590	60	(2.7%)	30	(6.5%)	7	(1.5%)	3	(1.6%)		
Washington	6,664,195	44	(2.0%)	5	(1.1%)	7	(1.5%)	7	(3.7%)		
West Virginia	1,819,777	35	(1.6%)	0	(0.0%)	10	(2.1%)	4	(2.1%)		
Wisconsin	5,654,774	34	(1.6%)	11	(2.4%)	22	(4.6%)	6	(3.2%)		
Wyoming	544,270	9	(0.4%)	0	(0.0%)	2	(0.4%)	4	(2.1%)		
<b>Total</b>	<b>307,006,550</b>	<b>2192</b>	<b>(100.0%)</b>	<b>463</b>	<b>(100.0%)</b>	<b>475</b>	<b>(100.0%)</b>	<b>188</b>	<b>(100.0%)</b>	<b>1502</b>	<b>(100.0%)</b>

<sup>§</sup> US Census Bureau, 2009

<sup>†</sup> Typhoidal *Salmonella* includes Typhi, Paratyphi A, Paratyphi B, and Paratyphi C

<sup>‡</sup> *Campylobacter* isolates are submitted only from FoodNet sites representing a total population 46,859,541. All *Campylobacter* isolates are received from Georgia, Maryland, New Mexico, Oregon, and Tennessee and every other isolate from California, Colorado, Connecticut, and New York; and every fifth isolate from Minnesota.

<sup>§</sup> Excluding Los Angeles County

<sup>¶</sup> Houston City

<sup>\*\*</sup> Los Angeles County

<sup>††</sup> Excluding New York City

<sup>†††</sup> Five boroughs of New York City (Bronx, Brooklyn, Manhattan, Queens, Staten Island)

<sup>§§</sup> Excluding Houston, Texas

### Surveillance Sites and Isolate Submissions

In 2009, NARMS conducted nationwide surveillance among approximately 307 million persons (2009 U.S. Census Bureau estimates). Public health laboratories systematically selected every 20<sup>th</sup> non-typhoidal *Salmonella*, *Shigella*, and *Escherichia coli* O157 isolate as well as every *Salmonella* ser. Typhi, *Salmonella* ser. Paratyphi A and *Salmonella* ser. Paratyphi C isolate received at their laboratories and forwarded these isolates to CDC for antimicrobial susceptibility testing. *Salmonella* ser. Paratyphi B was included in the every 20<sup>th</sup> sampling for non-typhoidal *Salmonella* because available laboratory methods do not always allow for consistent distinction between serotype Paratyphi B (which typically causes typhoidal illness) and serotype Paratyphi B var. L(+)-tartrate+ (which does not typically cause typhoidal illness).

Since 2005, public health laboratories of the 10 state health departments that participated in CDC's Foodborne Diseases Active Surveillance Network (FoodNet) have forwarded a representative sample of *Campylobacter* isolates to CDC for susceptibility testing. The FoodNet sites, representing approximately 47 million persons (2009 U.S. Census Bureau estimates), include California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee. Depending on the burden of *Campylobacter* in each FoodNet site, one of the following three methods was used to obtain a representative sample of *Campylobacter* isolates: all isolates received by Georgia, Maryland, New Mexico, Oregon, and Tennessee; every other isolate from California, Colorado, Connecticut, and New York; and every fifth isolate from Minnesota. From 1997 to 2004, one *Campylobacter* isolate was submitted each week from participating FoodNet sites.

### Testing of *Salmonella*, *Shigella*, and *Escherichia coli* O157

#### Antimicrobial Susceptibility Testing

*Salmonella*, *Shigella*, and *E. coli* O157 isolates were tested using broth microdilution (Sensititre<sup>®</sup>, Trek Diagnostics, Cleveland, OH) according to manufacturer's instructions to determine the minimum inhibitory concentration (MIC) for each of 15 antimicrobial agents: amikacin, ampicillin, amoxicillin-clavulanic acid, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole (Table 3). Before 2004, sulfamethoxazole was used instead of sulfisoxazole to represent the sulfonamides. Interpretive criteria defined by CLSI were used when available. The resistance breakpoint for amikacin, according to CLSI guidelines, is  $\geq 64$   $\mu\text{g}/\text{mL}$ . In 2002 and 2003, a truncated broth microdilution series was used for amikacin testing (0.5-4  $\mu\text{g}/\text{mL}$ ). For isolates that grew in all amikacin dilutions on the Sensititre panel (MIC > 4  $\mu\text{g}/\text{mL}$ ), ETest<sup>®</sup> (AB BIODISK, Solna, Sweden) was performed to determine amikacin MIC. The amikacin ETest<sup>®</sup> strip range of dilutions was 0.016-256  $\mu\text{g}/\text{mL}$ . Since 2004, amikacin had a full range of dilutions (0.5-64  $\mu\text{g}/\text{mL}$ ) on the Sensititre panel (CMV1AGNF).

In January 2010, CLSI published revised interpretive criteria for ceftriaxone and *Enterobacteriaceae*; the revised resistance breakpoint for ceftriaxone is MIC  $\geq 4$   $\mu\text{g}/\text{mL}$ . In this report, NARMS has applied the revised CLSI breakpoint for ceftriaxone resistance to data from all years.

**Table 3. Antimicrobial agents used for susceptibility testing for *Salmonella*, *Shigella*, and *Escherichia coli* O157 isolates, NARMS, 2009**

CLSI class	Antimicrobial Agent	Antimicrobial Agent Concentration Range (µg/mL)	MIC Interpretive Standard (µg/mL)		
			Susceptible	Intermediate	Resistant
Aminoglycosides	Amikacin	0.5–64	≤16	32	≥64
	Gentamicin	0.25–16	≤4	8	≥16
	Kanamycin	8–64	≤16	32	≥64
	Streptomycin*	32–64	≤32		≥64
β-lactam / β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid	1/0.5–32/16	≤8/4	16/8	≥32/16
Cephems	Cefoxitin	0.5–32	≤8	16	≥32
	Ceftiofur	0.12–8	≤2	4	≥8
	Ceftriaxone <sup>†</sup>	0.25–64	≤1	2	≥4
	Cephalothin <sup>‡</sup>	2–32	≤8	16	≥32
Folate pathway inhibitors	Sulfamethoxazole <sup>§</sup>	16–512	≤256		≥512
	Sulfisoxazole	16–256	≤256		≥512
	Trimethoprim-sulfamethoxazole	0.12/2.38–4/76	≤2/38		≥4/76
Penicillins	Ampicillin	1–32	≤8	16	≥32
Phenicol	Chloramphenicol	2–32	≤8	16	≥32
Quinolones	Ciprofloxacin	0.015–4	≤1	2	≥4
	Nalidixic acid	0.5–32	≤16		≥32
Tetracyclines	Tetracycline	4–32	≤4	8	≥16

\* No CLSI breakpoints; resistance breakpoint used in NARMS is ≥64 µg/mL.

<sup>†</sup> CLSI updated the ceftriaxone interpretive standards in January, 2010. Previous standards that were used for NARMS Human Isolate reports from 1996-2008 were susceptible ≤8 µg/mL, intermediate 16-32 µg/mL, and resistant ≥64 µg/mL.

<sup>‡</sup> Cephalothin was tested from 1996 to 2003 for *Salmonella*, *Shigella*, and *E. coli* O157.

<sup>§</sup> Sulfamethoxazole, which was tested during 1996–2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.

## Additional Testing of *Salmonella* Strains

### Cephalosporin Retesting of Isolates from 1996-1998

Review of *Salmonella* isolates tested in NARMS during 1996 to 1998 gave conflicting cephalosporin susceptibility results. In particular, some isolates previously reported in NARMS as ceftiofur-resistant exhibited a low ceftriaxone MIC and, in some cases, did not exhibit an elevated MIC to other  $\beta$ -lactams. Because these findings suggested that some previously reported results were inaccurate, we retested, using the 2003 NARMS Sensitivity<sup>®</sup> plate, isolates of *Salmonella* tested in NARMS during 1996 to 1998 that exhibited an MIC  $\geq 2$   $\mu\text{g/mL}$  to ceftiofur or ceftriaxone. The retest results have been included in the NARMS annual reports since 2003.

### Serotype Confirmation/Categorization

*Salmonella* serotype reported by the submitting laboratory was used for reporting with few exceptions. Serotype was confirmed by CDC for isolates that underwent subsequent molecular analysis for publication. Because of challenges associated with interpretation of tartrate fermentation assays, ability to ferment tartrate was confirmed for isolates reported as *Salmonella* ser. Paratyphi B by the submitting laboratory (serotype Paratyphi B is by definition unable to ferment L(+) tartrate). To distinguish *Salmonella* serotypes Paratyphi B and Paratyphi B var L(+) tartrate+ (formerly serotype Java), CDC performed Jordan's tartrate test and/or Kauffmann's tartrate test on all *Salmonella* ser. Paratyphi B isolates from 1996 to 2009 for which the tartrate result was not reported or was reported to be negative. Isolates negative for tartrate fermentation by both assays were categorized as serotype Paratyphi B. Isolates that were positive for tartrate fermentation by either assay were categorized as serotype Paratyphi B var L(+) tartrate+. Confirmation of other biochemical reactions or somatic and flagellar antigens was not performed at CDC.

Because of increased submissions of *Salmonella* ser. I 4,[5],12:i:- noted in previous years, and recognition of the possibility that this serotype may have been underreported in previous years, isolates reported as serogroup B and tested in NARMS during 1996 to 2009 were reviewed for additional information; isolates that could be clearly identified as serogroup B, first-phase flagellar antigen "i", second phase flagellar antigen absent were categorized in this report as *Salmonella* ser. I 4,[5],12:i:-.

## Testing of *Campylobacter*

### Changes in Testing Methods in 2005

Starting in 2005, there were four changes in the methodology used for *Campylobacter*. First, a surveillance scheme for selecting a representative sample of *Campylobacter* isolates for submission by FoodNet sites was implemented. State public health laboratories within FoodNet sites receive *Campylobacter* isolates from reference and clinical laboratories within their state. In 2005, FoodNet sites changed from submitting the first isolate received each week to submitting every isolate (Georgia, Maryland, New Mexico, Oregon, and Tennessee), every other isolate (California, Colorado, Connecticut, and New York), or every fifth isolate received (Minnesota). The number of laboratories submitting isolates ranged from two to all. Second, the method of species identification was updated to parallel what is used by the CDC National *Campylobacter* Laboratory. Third, the susceptibility testing method changed from Etest<sup>®</sup> (AB bioMerieux, Solna, Sweden) to broth microdilution. Fourth, there were changes in the antimicrobial agents tested. Florfenicol replaced chloramphenicol as the phenicol class representative drug, and telithromycin was added to the NARMS panel of agents tested. These methods began in 2005 and continue through the current year's report.

### Identification/Speciation and Antimicrobial Susceptibility Testing

From 2005 through 2009, isolates were confirmed as *Campylobacter* by determination of typical morphology and motility using dark-field microscopy and a positive oxidase test reaction. Identification of *C. jejuni* was performed using the hippurate hydrolysis test. Hippurate-positive isolates were identified as *C. jejuni*. Hippurate-negative isolates were further characterized with polymerase chain reaction (PCR) assays with specific targets for *C. jejuni* (*mapA* or *hipO* gene), *C. coli*-specific *ceuE* gene (Linton *et al.* 1997, Gonzales *et al.* 1997, Pruckler *et al.* 2006), or other species specific primers. From 2003 to 2004, putative *Campylobacter* isolates were identified as *C. jejuni* or *C. coli* using BAX<sup>®</sup> System PCR Assay according to the manufacturer's instructions (DuPont Qualicon, Wilmington, DE). Isolates not identified as *C. jejuni* or *C. coli* were further characterized by other PCR assays

(Linton *et al.* 1996) or were characterized by the CDC National *Campylobacter* Reference Laboratory. From 1997 to 2002, methodology similar to that used from 2005 to 2009 was used.

The methods for susceptibility testing *Campylobacter* and criteria for interpreting the results have changed during the course of NARMS surveillance. Beginning in 2005, broth microdilution using the Sensititre® system (Trek Diagnostics, Cleveland, OH) was performed according to manufacturer’s instructions to determine the MICs for nine antimicrobial agents: azithromycin, ciprofloxacin, clindamycin, erythromycin, florfenicol, gentamicin, nalidixic acid, telithromycin, and tetracycline (Table 4). CLSI recommendations for quality control were followed. From 1997 to 2004, Etest® (AB bioMerieux, Solna, Sweden) was used for susceptibility testing of *Campylobacter* isolates. *Campylobacter*-specific CLSI interpretive criteria were used for erythromycin, ciprofloxacin, and tetracycline beginning with the 2004 NARMS annual report. NARMS breakpoints were used when CLSI breakpoints were not available. Beginning in 2004, NARMS breakpoints were established based on the MIC distributions of NARMS isolates and the presence of known resistance genes or mutations. In pre-2004 annual reports, NARMS breakpoints used were based on those available for other organisms. Establishment of breakpoints based on MIC distributions resulted in higher MIC definitions for azithromycin and erythromycin resistance compared with those reported in pre-2004 annual reports. The breakpoints listed in Table 4 have been applied to MIC data collected for all years so that resistance prevalence is comparable over time.

**Table 4. Antimicrobial agents used for susceptibility testing of *Campylobacter* isolates, NARMS, 1997–2009**

CLSI class	Antimicrobial Agent	Antimicrobial Agent Concentration Range (µg/mL)	MIC Interpretive Standard (µg/mL)		
			Susceptible	Intermediate	Resistant
Aminoglycosides	Gentamicin	0.12–32 0.016–256*	≤2	4	≥8
Ketolides	Telithromycin†	0.015–8	≤4	8	≥16
Lincosamides	Clindamycin	0.03–16 0.016–256*	≤2	4	≥8
Macrolides	Azithromycin	0.015–64 0.016–256*	≤2	4	≥8
	Erythromycin	0.03–64 0.016–256*	≤8	16	≥32
Phenicol	Chloramphenicol‡	0.016–256*	≤8	16	≥32
	Florfenicol§	0.03–64	≤4	N/A	N/A
Quinolones	Ciprofloxacin	0.015–64 0.002–32	≤1	2	≥4
	Nalidixic acid	4–64 0.016–256*	≤16	32	≥64
Tetracyclines	Tetracycline	0.06–64 0.016–256*	≤4	8	≥16

\* Etest dilution range used from 1997–2004.

† Telithromycin added to NARMS panel in 2005.

‡ Chloramphenicol, tested from 1997–2004, was replaced by florfenicol in 2005.

§ Currently only a susceptible breakpoint (≤4 µg/mL) has been established. In this report isolates with a MIC ≥8 µg/mL are categorized as resistant.

## Retesting

Known mechanisms of quinolone resistance in *Campylobacter* are expected to confer equivalent susceptibilities to nalidixic acid and ciprofloxacin. Similarly, known mechanisms of macrolide resistance are expected to confer equivalent susceptibilities to erythromycin and azithromycin. Confirmatory testing of isolates with conflicting results was performed by broth microdilution methods (Sensititre®, Trek Diagnostics, Cleveland, OH). Totals reported here reflect the retest results.

## Data Analysis

For all pathogens, MICs were categorized as resistant, intermediate (if applicable), or susceptible. Analysis was restricted to the first isolate received (per genus under surveillance) per patient in the calendar year. If two or more isolates were received for the same patient for *Salmonella* ser. Typhi, the first blood isolate collected would be included in analysis. If no blood isolates were submitted, the first isolate collected would be included in analysis. Where established, CLSI interpretive criteria were used; streptomycin resistance was defined as MIC  $\geq 64$   $\mu\text{g/mL}$  (Table 3). The 95% confidence intervals (CIs) for the percentage of resistant isolates are included in the MIC distribution tables. The 95% CIs were calculated using the Paulson-Camp-Pratt approximation method.

When describing results for several years, multidrug resistance for *Salmonella*, *Shigella*, and *E. coli* O157 isolates was limited to the eight CLSI classes (Table 3) tested in all years from 1996 through 2009 represented by 15 agents: amikacin, amoxicillin-clavulanic acid, ampicillin, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole. When describing multidrug resistance for several years for *Campylobacter* isolates, multidrug resistance was limited to the five CLSI classes tested in all years from 1997 through 2009, represented by ciprofloxacin, chloramphenicol/florfenicol, clindamycin, erythromycin, nalidixic acid, and tetracycline.

Logistic regression was used to compare the prevalence of antimicrobial resistance among *Salmonella* and *Campylobacter* isolates tested in 2009 with the reference, which was the average prevalence of resistance in the first five years that NARMS surveillance was nationwide (2003–07). The analysis included the following:

1. Non-typhoidal *Salmonella*: resistance to nalidixic acid, resistance to ceftriaxone, resistance to one or more CLSI classes, resistance to three more CLSI classes
2. *Salmonella* ser. Enteritidis: resistance to nalidixic acid
3. *Salmonella* ser. Typhimurium: resistance to at least ACSSuT (ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline)
4. *Salmonella* ser. Newport: resistance to at least ACSSuTAuCx (ACSSuT, amoxicillin-clavulanic acid, and ceftriaxone)
5. *Salmonella* ser. Typhi: resistance to nalidixic acid
6. *Campylobacter* species: resistance to ciprofloxacin
7. *Campylobacter jejuni*: resistance to ciprofloxacin

To account for site-to-site variation in the prevalence of antimicrobial resistance, we included main effects adjustments for site in the analysis. The final regression models for *Salmonella* adjusted for the submitting site using the nine geographic regions described in the Public Health Laboratory Information System (PHLIS): East North Central, East South Central, Mid-Atlantic, Mountain, New England, Pacific, South Atlantic, West North Central, and West South Central. For *Campylobacter*, the final regression models adjusted for the submitting FoodNet site. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional maximum likelihood estimation. The adequacy of model fit was assessed in several ways. The significance of the main effect of year was assessed using the likelihood ratio test. The likelihood ratio test was also used to test for significance of interaction between site and year, although the power of the test to detect a single site-specific interaction was low. The Hosmer and Lemeshow goodness-of-fit test was also used. Finally, residual analysis was performed to examine the influence of individual observations. Having assessed that the main effect of year was significant, we reported ORs with 95% CIs (for 2009 compared with reference) that did not include 1.00 as statistically significant.







**Table 6. Percentage and number of non-typhoidal *Salmonella* isolates resistant to antimicrobial agents, 2000–2009**

Year		2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates		1372	1410	1998	1855	1782	2034	2173	2144	2380	2192
Rank <sup>*</sup>	CLSI <sup>†</sup> Antimicrobial Class	Antibiotic (Resistance breakpoint)									
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		Gentamicin (MIC ≥ 16)	2.7%	1.9%	1.4%	1.4%	1.3%	2.2%	2.0%	2.1%	1.5%
		Streptomycin (MIC ≥ 64)	16.3%	17.1%	13.2%	15.0%	12.0%	11.1%	10.7%	10.4%	10.0%
	β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid (MIC ≥ 32/16)	3.9%	4.7%	5.3%	4.6%	3.7%	3.2%	3.7%	3.3%	3.1%
			54	66	106	86	66	65	81	70	73
	Cephems	Ceftiofur (MIC ≥ 8)	3.2%	4.1%	4.4%	4.5%	3.4%	2.9%	3.6%	3.3%	3.0%
		Ceftriaxone (MIC ≥ 64)	3.2%	3.7%	4.4%	4.4%	3.3%	2.9%	3.7%	3.3%	3.0%
	Penicillins	Ampicillin (MIC ≥ 32)	15.9%	17.5%	13.0%	13.6%	12.1%	11.4%	11.0%	10.1%	9.7%
			218	247	259	253	216	232	238	217	231
	Quinolones	Ciprofloxacin (MIC ≥ 4)	0.4%	0.2%	0.1%	0.2%	0.2%	0.0%	0.1%	0.1%	0.1%
Nalidixic acid (MIC ≥ 32)		2.3%	2.3%	1.6%	1.9%	2.2%	1.9%	2.4%	2.3%	2.0%	
II	Aminoglycosides	Kanamycin (MIC ≥ 64)	5.6%	4.8%	3.8%	3.5%	2.8%	3.4%	2.9%	2.8%	2.1%
			77	68	76	64	50	70	63	61	50
	Cephems	Cefoxitin (MIC ≥ 32)	3.2%	3.4%	4.3%	4.3%	3.4%	3.0%	3.5%	2.9%	3.0%
		Cephalothin (MIC ≥ 32)	4.0%	4.0%	5.1%	5.3%	Not Tested				
	Folate pathway inhibitors	Sulfamethoxazole/Sulfisoxazole <sup>‡</sup> (MIC ≥ 512)	17.1%	17.8%	12.9%	15.1%	13.3%	12.6%	12.1%	12.3%	10.1%
		Trimethoprim-sulfamethoxazole (MIC ≥ 4/76)	2.0%	2.0%	1.4%	1.9%	1.7%	1.7%	1.7%	1.5%	1.6%
	Phenicol	Chloramphenicol (MIC ≥ 32)	10.1%	11.6%	8.6%	10.1%	7.6%	7.8%	6.4%	7.3%	6.2%
			138	164	172	187	136	159	139	156	147
	Tetracyclines	Tetracycline (MIC ≥ 16)	18.7%	19.9%	14.9%	16.3%	13.6%	13.9%	13.5%	14.5%	11.6%
			256	280	298	303	242	282	293	310	275

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.

**Table 7. Resistance patterns of non-typhoidal *Salmonella* isolates, 2000–2009**

Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates	1372	1410	1998	1855	1782	2034	2173	2144	2380	2192
	%	%	%	%	%	%	%	%	%	%
	n	n	n	n	n	n	n	n	n	n
No resistance detected	74.5%	72.5%	79.1%	78.0%	80.0%	80.9%	80.5%	81.1%	84.0%	83.2%
	1022	1022	1580	1447	1425	1646	1749	1738	1999	1823
Resistance ≥ 1 CLSI class*	25.5%	27.5%	20.9%	22.0%	20.0%	19.1%	19.5%	18.9%	16.0%	16.8%
	350	388	418	408	357	388	424	406	381	369
Resistance ≥ 2 CLSI classes*	20.0%	22.1%	15.8%	17.5%	15.0%	14.8%	14.7%	14.2%	12.4%	13.0%
	275	311	315	325	267	302	319	305	295	284
Resistance ≥ 3 CLSI classes*	15.6%	16.7%	12.3%	14.2%	11.4%	12.0%	11.8%	11.1%	9.4%	9.5%
	214	236	245	263	204	244	256	239	224	209
Resistance ≥ 4 CLSI classes*	12.7%	13.5%	9.8%	11.4%	9.3%	9.1%	8.1%	8.2%	7.4%	7.3%
	174	191	195	211	165	185	177	176	177	159
Resistance ≥ 5 CLSI classes*	9.5%	10.3%	8.2%	9.8%	8.0%	7.2%	6.3%	6.9%	6.6%	6.3%
	131	145	164	182	142	146	137	149	157	137
At least ACSSuT <sup>†</sup>	8.9%	10.1%	7.8%	9.3%	7.2%	6.9%	5.6%	6.3%	5.8%	5.1%
	122	142	156	173	129	141	121	136	138	112
At least ACT/S <sup>‡</sup>	0.9%	0.5%	1.1%	1.2%	0.6%	0.9%	0.7%	0.7%	0.5%	0.7%
	13	7	21	23	10	18	15	16	11	15
At least ACSSuTAuCx <sup>§</sup>	2.6%	2.6%	3.4%	3.2%	2.4%	2.0%	2.0%	2.1%	1.8%	1.4%
	35	36	67	60	42	41	43	46	44	30
At least ceftriaxone and nalidixic acid resistant	0.1%	0.1%	0.2%	0.1%	0.1%	0.1%	0.1%	0.2%	0.0%	0.2%
	1	2	4	2	2	2	3	5	0	4

\* CLSI: Clinical and Laboratory Standards Institute

† ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline

‡ ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole

§ ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone

**Table 8. Twenty most common non-typhoidal *Salmonella* serotypes in NARMS, 2009**

NARMS		Isolates	
Rank	Serotype	n	(%)
1	Enteritidis	410	(18.7%)
2	Typhimurium	371	(16.9%)
3	Newport	236	(10.8%)
4	Javiana	105	(4.8%)
5	Heidelberg	86	(3.9%)
6	14,[5],12:i:-	72	(3.3%)
7	Oranienburg	64	(2.9%)
8	Saintpaul	57	(2.6%)
9	Montevideo	56	(2.6%)
10	Braenderup	46	(2.1%)
11	Infantis	44	(2.0%)
12	Muenchen	42	(1.9%)
13	Mississippi	28	(1.3%)
14	Thompson	27	(1.2%)
15	Agona	21	(1.0%)
16	Bareilly	20	(0.9%)
17	Litchfield	20	(0.9%)
18	Paratyphi B var. L(+) tartrate+	20	(0.9%)
19	Hadar	19	(0.9%)
20	Poona	16	(0.7%)
<b>Subtotal</b>		<b>1760</b>	<b>(80.3%)</b>
	All other serotypes	373	(17.0%)
	Unknown serotype	19	(0.9%)
	Partially serotyped	20	(0.9%)
	Rough/Nonmotile isolates	20	(0.9%)
<b>Subtotal</b>		<b>432</b>	<b>(19.7%)</b>
<b>Grand Total</b>		<b>2192</b>	<b>(100.0%)</b>


**A. *Salmonella ser. Enteritidis***

**Table 9. Minimum inhibitory concentrations (MICs) and resistance of *Salmonella ser. Enteritidis* isolates to antimicrobial agents, 2009 (N=410)**

Rank*	CLSI† Antimicrobial Class	Antimicrobial Agent	% of isolates			Percent of all isolates with MIC (µg/mL)**												
			%‡	%R§	[95% CI]¶	0.015	0.03	0.06	0.125	0.25	0.50	1	2	4	8	16	32	64
I	Aminoglycosides	Amikacin	0.0	0.0	[0.0 - 0.9]	[Shaded area from 0.015 to 0.50]												
		Gentamicin	0.0	0.0	[0.0 - 0.9]	[Shaded area from 0.015 to 0.50]												
		Streptomycin	N/A	1.2	[0.4 - 2.8]	[Shaded area from 0.015 to 0.50]												
	β-lactam / β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid	0.2	0.0	[0.0 - 0.9]	[Shaded area from 0.015 to 0.50]												
		Cephems	0.0	0.0	[0.0 - 0.9]	[Shaded area from 0.015 to 0.50]												
	Penicillins	Ceftiofur	0.0	0.0	[0.0 - 0.9]	[Shaded area from 0.015 to 0.50]												
		Ceftriaxone	0.0	0.0	[0.0 - 0.9]	[Shaded area from 0.015 to 0.50]												
	Quinolones	Ampicillin	0.0	3.9	[2.2 - 6.3]	[Shaded area from 0.015 to 0.50]												
		Ciprofloxacin	0.0	0.0	[0.0 - 0.9]	[Shaded area from 0.015 to 0.50]												
II	Aminoglycosides	Nalidixic acid	N/A	3.7	[2.1 - 6.0]	[Shaded area from 0.015 to 0.50]												
		Kanamycin	0.0	0.2	[0.00 - 1.3]	[Shaded area from 0.015 to 0.50]												
	Cephems	Cefoxitin	0.0	0.0	[0.0 - 0.9]	[Shaded area from 0.015 to 0.50]												
		Folate pathway inhibitors	Sulfisoxazole	N/A	1.7	[0.7 - 3.5]	[Shaded area from 0.015 to 0.50]											
	Phenicol	Trimethoprim-sulfamethoxazole	N/A	0.7	[0.1 - 2.1]	[Shaded area from 0.015 to 0.50]												
		Chloramphenicol	0.2	0.0	[0.0 - 0.9]	[Shaded area from 0.015 to 0.50]												
	Tetracyclines	Tetracycline	0.2	1.2	[0.4 - 2.8]	[Shaded area from 0.015 to 0.50]												

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table 1): Rank 1, Critically Important; Rank 2, Highly Important  
 † CLSI: Clinical and Laboratory Standards Institute  
 ‡ Percent of isolates with intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists  
 § Percent of isolates that were resistant  
 ¶ The 95% confidence intervals (CI) for percent resistant (%R) were calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method. The 95% CI is presented to summarize uncertainty in the observed resistance (R%).  
 \*\* The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the percentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.

**Figure 14. Antimicrobial resistance pattern for *Salmonella ser. Enteritidis*, 2009**



**Table 10. Percentage and number of *Salmonella ser. Enteritidis* isolates resistant to antimicrobial agents, 2000–2009**

Year			2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates			319	277	337	257	271	384	413	385	439	410
Rank*	CLSI† Antimicrobial Class	Antibiotic (Resistance breakpoint)										
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		Gentamicin (MIC ≥ 16)	0.3%	0.0%	0.3%	0.4%	0.4%	0.8%	0.2%	0.0%	0.2%	0.0%
		Streptomycin (MIC ≥ 64)	0.0%	1.4%	1.5%	1.2%	2.2%	1.0%	1.2%	0.5%	0.5%	1.2%
	β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid (MIC ≥ 32/16)	0.0%	1.4%	0.6%	0.0%	0.0%	0.8%	0.5%	0.5%	0.0%	0.0%
		Cephems										
	Cephems	Ceftiofur (MIC ≥ 8)	0.0%	2.2%	0.0%	0.0%	0.0%	0.5%	0.5%	0.3%	0.0%	0.0%
		Ceftriaxone (MIC ≥ 64)	0.0%	1.4%	0.0%	0.0%	0.0%	0.3%	0.5%	0.3%	0.0%	0.0%
	Penicillins	Ampicillin (MIC ≥ 32)	7.5%	8.7%	6.8%	2.3%	4.1%	2.9%	4.4%	2.1%	3.6%	3.9%
		Quinolones										
	Quinolones	Ciprofloxacin (MIC ≥ 4)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Nalidixic acid (MIC ≥ 32)		2.2%	4.3%	3.9%	4.7%	6.6%	4.7%	7.0%	5.7%	6.6%	3.7%	
II	Aminoglycosides	Kanamycin (MIC ≥ 64)	0.3%	0.7%	0.3%	0.0%	0.7%	0.3%	0.2%	0.5%	0.0%	0.2%
		Cephems										
	Cephems	Cefoxitin (MIC ≥ 32)	0.0%	0.4%	0.0%	0.0%	0.0%	1.0%	0.5%	0.3%	0.0%	0.0%
		Cephalothin (MIC ≥ 32)	0.9%	1.1%	0.6%	1.2%	Not Tested					
	Folate pathway inhibitors	Sulfamethoxazole/Sulfisoxazole‡ (MIC ≥ 512)	0.9%	2.2%	1.5%	1.2%	1.8%	1.6%	1.5%	1.6%	1.1%	1.7%
		Trimethoprim-sulfamethoxazole (MIC ≥ 4/76)	0.0%	0.7%	0.6%	0.8%	0.0%	0.5%	0.5%	1.0%	0.9%	0.7%
	Phenicol	Chloramphenicol (MIC ≥ 32)	0.0%	0.0%	0.3%	0.4%	0.4%	0.5%	0.0%	0.5%	0.5%	0.0%
		Tetracyclines										
	Tetracyclines	Tetracycline (MIC ≥ 16)	1.9%	1.8%	4.2%	1.6%	3.3%	2.3%	1.7%	3.9%	1.6%	1.2%


\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.



**Figure 15. Antimicrobial resistance pattern for *Salmonella ser. Typhimurium*, 2009**



**Table 13. Percentage and number of *Salmonella ser. Typhimurium* isolates resistant to antimicrobial agents, 2000–2009**

Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009		
<b>Total Isolates</b>	<b>304</b>	<b>325</b>	<b>394</b>	<b>408</b>	<b>383</b>	<b>438</b>	<b>409</b>	<b>404</b>	<b>397</b>	<b>371</b>		
Rank <sup>*</sup>	CLSI <sup>†</sup> Antimicrobial Class	Antibiotic (Resistance breakpoint)										
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
		Gentamicin (MIC ≥ 16)	2.6%	1.5%	2.3%	2.0%	2.1%	1.8%	2.7%	2.5%	1.5%	1.9%
		Streptomycin (MIC ≥ 64)	39.5%	40.0%	32.0%	35.5%	31.9%	28.1%	29.3%	32.4%	28.5%	25.9%
	β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid (MIC ≥ 32/16)	6.3%	6.2%	7.6%	5.6%	4.7%	3.2%	4.4%	6.7%	3.3%	6.2%
		Cephems	Cefotiofur (MIC ≥ 8)	3.6%	3.1%	4.3%	4.9%	4.4%	2.5%	4.2%	6.4%	3.3%
		Ceftriaxone (MIC ≥ 64)	3.3%	3.1%	4.3%	4.9%	4.4%	2.5%	4.2%	6.4%	3.3%	6.5%
	Penicillins	Ampicillin (MIC ≥ 32)	42.1%	42.5%	33.8%	36.3%	32.1%	29.0%	28.1%	31.7%	26.2%	28.0%
		Quinolones	Ciprofloxacin (MIC ≥ 4)	0.0%	0.3%	0.0%	0.0%	0.0%	0.0%	0.2%	0.0%	0.0%
		Nalidixic acid (MIC ≥ 32)	1.3%	0.6%	1.3%	1.2%	0.5%	0.9%	0.7%	1.5%	1.3%	2.2%
	II	Aminoglycosides	Kanamycin (MIC ≥ 64)	13.2%	8.3%	7.6%	7.1%	5.7%	5.7%	5.1%	5.9%	2.3%
Cephems			Ceftioxin (MIC ≥ 32)	3.6%	3.1%	4.3%	4.4%	4.7%	2.5%	3.9%	5.7%	3.3%
		Cephalothin (MIC ≥ 32)	4.3%	3.1%	5.6%	6.1%	Not Tested					
Folate pathway inhibitors		Sulfamethoxazole/Sulfisoxazole <sup>‡</sup> (MIC ≥ 512)	45.4%	43.1%	32.2%	38.7%	36.0%	32.0%	33.3%	37.4%	30.2%	29.9%
		Trimethoprim-sulfamethoxazole (MIC ≥ 4/76)	3.6%	2.5%	2.3%	3.4%	2.6%	2.7%	2.2%	2.5%	1.8%	3.0%
Phenicol		Chloramphenicol (MIC ≥ 32)	30.9%	31.7%	23.4%	28.2%	24.3%	24.4%	22.0%	25.5%	23.2%	20.5%
		Tetracyclines	Tetracycline (MIC ≥ 16)	43.4%	43.4%	32.0%	38.2%	30.3%	30.4%	31.5%	36.9%	27.5%


\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.



**Figure 16. Antimicrobial resistance pattern for *Salmonella ser. Newport*, 2009**



**Table 16. Percentage and number of *Salmonella ser. Newport* isolates resistant to antimicrobial agents, 2000–2009**

Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009		
<b>Total Isolates</b>	<b>121</b>	<b>124</b>	<b>241</b>	<b>223</b>	<b>191</b>	<b>207</b>	<b>217</b>	<b>221</b>	<b>253</b>	<b>236</b>		
Rank*	CLSI† Antimicrobial Class	Antibiotic (Resistance breakpoint)										
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
		Gentamicin (MIC ≥ 16)	2.5%	3.2%	3.3%	3.1%	0.5%	1.0%	0.9%	0.9%	0.4%	0.4%
		Streptomycin (MIC ≥ 64)	24.0%	31.5%	25.3%	24.2%	15.7%	14.0%	13.8%	10.4%	14.2%	7.6%
	β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid (MIC ≥ 32/16)	22.3%	26.6%	22.8%	21.5%	15.2%	12.6%	12.4%	8.1%	13.0%	6.8%
		Cephems	Ceftiofur (MIC ≥ 8)	22.3%	27.4%	22.8%	22.0%	15.2%	12.6%	12.4%	8.1%	13.0%
	Cephems	Ceftriaxone (MIC ≥ 64)	22.3%	25.8%	22.8%	21.5%	14.7%	12.6%	12.9%	8.1%	13.0%	6.4%
		Penicillins	Ampicillin (MIC ≥ 32)	23.1%	29.8%	24.9%	22.9%	15.7%	14.0%	15.2%	10.0%	15.0%
	Quinolones	Ciprofloxacin (MIC ≥ 4)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		Nalidixic acid (MIC ≥ 32)	0.8%	0.0%	0.8%	0.4%	0.5%	0.0%	0.5%	0.0%	0.4%	0.0%
	II	Aminoglycosides	Kanamycin (MIC ≥ 64)	5.0%	7.3%	10.0%	4.5%	2.6%	1.9%	2.3%	0.9%	3.6%
Cephems			Cefoxitin (MIC ≥ 32)	22.3%	25.8%	22.4%	21.5%	15.2%	12.6%	12.9%	8.1%	13.0%
Folate pathway inhibitors		Cephalothin (MIC ≥ 32)	22.3%	26.6%	22.8%	22.4%	Not Tested					
		Sulfamethoxazole/Sulfisoxazole‡ (MIC ≥ 512)	23.1%	32.3%	25.7%	24.7%	16.8%	15.5%	15.2%	10.4%	13.8%	8.1%
Folate pathway inhibitors		Trimethoprim-sulfamethoxazole (MIC ≥ 4/76)	4.1%	1.6%	4.1%	0.9%	2.1%	1.9%	3.2%	1.8%	3.2%	0.4%
		Phenicol	Chloramphenicol (MIC ≥ 32)	23.1%	28.2%	25.3%	22.4%	15.2%	13.5%	12.4%	9.5%	12.6%
Tetracyclines		Tetracycline (MIC ≥ 16)	23.1%	30.6%	25.7%	24.2%	16.8%	14.5%	14.3%	10.0%	14.6%	8.1%


\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.



**Figure 17. Antimicrobial resistance pattern for *Salmonella ser. Heidelberg*, 2009**



**Table 19. Percentage and number of *Salmonella ser. Heidelberg* isolates resistant to antimicrobial agents, 2000–2009**

Year			2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates			79	102	105	96	92	125	102	98	75	86
Rank*	CLSI† Antimicrobial Class	Antibiotic (Resistance breakpoint)										
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		Gentamicin (MIC ≥ 16)	8.9%	7.8%	3.8%	5.2%	4.3%	6.4%	4.9%	16.3%	14.7%	2.3%
		Streptomycin (MIC ≥ 64)	22.8%	25.5%	17.1%	12.5%	15.2%	13.6%	11.8%	12.2%	30.7%	23.3%
	β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid (MIC ≥ 32/16)	3.8%	2.9%	9.5%	5.2%	9.8%	8.8%	9.8%	7.1%	8.0%	20.9%
		Cephems										
	Cephems	Ceftiofur (MIC ≥ 8)	3.8%	2.9%	7.6%	5.2%	8.7%	8.8%	9.8%	7.1%	8.0%	20.9%
		Ceftriaxone (MIC ≥ 64)	3.8%	2.9%	7.6%	5.2%	8.7%	8.8%	9.8%	7.1%	8.0%	20.9%
	Penicillins	Ampicillin (MIC ≥ 32)	10.1%	9.8%	12.4%	10.4%	25.0%	20.0%	18.6%	18.4%	28.0%	27.9%
		Quinolones										
	Quinolones	Ciprofloxacin (MIC ≥ 4)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		Nalidixic acid (MIC ≥ 32)	1.3%	0.0%	0.0%	1.0%	0.0%	0.8%	0.0%	0.0%	0.0%	0.0%
II	Aminoglycosides	Kanamycin (MIC ≥ 64)	15.2%	19.6%	10.5%	8.3%	8.7%	12.8%	8.8%	11.2%	26.7%	20.9%
		Cephems										
	Cephems	Cefoxitin (MIC ≥ 32)	2.5%	2.9%	8.6%	5.2%	7.6%	8.8%	8.8%	7.1%	8.0%	19.8%
		Cephalothin (MIC ≥ 32)	5.1%	3.9%	10.5%	7.3%	Not Tested					
	Folate pathway inhibitors	Sulfamethoxazole/Sulfisoxazole‡ (MIC ≥ 512)	11.4%	8.8%	6.7%	7.3%	7.6%	8.0%	4.9%	18.4%	12.0%	7.0%
		Trimethoprim-sulfamethoxazole (MIC ≥ 4/76)	1.3%	2.0%	1.0%	2.1%	0.0%	0.8%	0.0%	0.0%	2.7%	3.5%
	Phenicol	Chloramphenicol (MIC ≥ 32)	1.3%	1.0%	1.0%	0.0%	1.1%	0.8%	0.0%	3.1%	1.3%	4.7%
		Tetracyclines										
	Tetracyclines	Tetracycline (MIC ≥ 16)	21.5%	24.5%	19.0%	16.7%	19.6%	18.4%	13.7%	22.4%	36.0%	27.9%


\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.



**Figure 18. Antimicrobial resistance pattern for *Salmonella ser. I 4,[5],12:i:-*, 2009**



**Table 22. Percentage and number of *Salmonella ser. I 4,[5],12:i:-* isolates resistant to antimicrobial agents, 2000–2009**

Year			2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates			13	14	35	37	36	33	105	73	83	72
Rank*	CLSI <sup>†</sup> Antimicrobial Class	Antibiotic (Resistance breakpoint)										
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		Gentamicin (MIC ≥ 16)	0.0%	7.1%	0.0%	5.4%	5.6%	0.0%	4.8%	1.4%	3.6%	2.8%
		Streptomycin (MIC ≥ 64)	7.7%	14.3%	2.9%	8.1%	5.6%	3.0%	3.8%	8.2%	10.8%	12.5%
	β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid (MIC ≥ 32/16)	0.0%	0.0%	2.9%	5.4%	2.8%	3.0%	3.8%	1.4%	3.6%	4.2%
		Cephems										
	Cephems	Cefiofur (MIC ≥ 8)	0.0%	7.1%	2.9%	5.4%	2.8%	3.0%	3.8%	2.7%	3.6%	2.8%
		Ceftriaxone (MIC ≥ 64)	0.0%	0.0%	2.9%	5.4%	2.8%	3.0%	3.8%	2.7%	3.6%	2.8%
	Penicillins	Ampicillin (MIC ≥ 32)	7.7%	7.1%	8.6%	8.1%	5.6%	6.1%	6.7%	5.5%	8.4%	11.1%
		Quinolones										
	Quinolones	Ciprofloxacin (MIC ≥ 4)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Nalidixic acid (MIC ≥ 32)		0.0%	0.0%	0.0%	2.7%	2.8%	0.0%	1.0%	1.4%	1.2%	0.0%	
II	Aminoglycosides	Kanamycin (MIC ≥ 64)	0.0%	7.1%	0.0%	0.0%	0.0%	0.0%	0.0%	1.4%	1.2%	0.0%
		Cephems										
	Cephems	Cefoxitin (MIC ≥ 32)	Not Tested	0.0%	2.9%	5.4%	2.8%	3.0%	3.8%	1.4%	3.6%	2.8%
		Cephalothin (MIC ≥ 32)	0.0%	7.1%	2.9%	5.4%	Not Tested					
	Folate pathway inhibitors	Sulfamethoxazole/Sulfisoxazole <sup>‡</sup> (MIC ≥ 512)	0.0%	14.3%	2.9%	5.4%	11.1%	0.0%	8.6%	4.1%	13.3%	13.9%
		Trimethoprim-sulfamethoxazole (MIC ≥ 4/76)	0.0%	7.1%	2.9%	0.0%	2.8%	0.0%	0.0%	1.4%	4.8%	1.4%
	Phenicol	Chloramphenicol (MIC ≥ 32)	0.0%	7.1%	2.9%	0.0%	2.8%	0.0%	1.9%	1.4%	6.0%	8.3%
		Tetracyclines										
	Tetracyclines	Tetracycline (MIC ≥ 16)	7.7%	7.1%	5.7%	0.0%	11.1%	3.0%	8.6%	9.6%	16.9%	16.7%

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.

**Table 23. Resistance patterns of *Salmonella* ser. I 4,[5],12:i:- isolates, 2000–2009**

Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
<b>Total Isolates</b>	<b>13</b>	<b>14</b>	<b>35</b>	<b>37</b>	<b>36</b>	<b>33</b>	<b>105</b>	<b>73</b>	<b>83</b>	<b>72</b>
	% n									
No resistance detected	92.3% 12	78.6% 11	91.4% 32	78.4% 29	80.6% 29	87.9% 29	85.7% 90	82.2% 60	77.1% 64	76.4% 55
Resistance ≥ 1 CLSI class*	7.7% 1	21.4% 3	8.6% 3	21.6% 8	19.4% 7	12.1% 4	14.3% 15	17.8% 13	22.9% 19	23.6% 17
Resistance ≥ 2 CLSI classes*	7.7% 1	14.3% 2	8.6% 3	10.8% 4	13.9% 5	3.0% 1	11.4% 12	6.8% 5	16.9% 14	16.7% 12
Resistance ≥ 3 CLSI classes*	7.7% 1	7.1% 1	5.7% 2	5.4% 2	8.3% 3	3.0% 1	9.5% 10	5.5% 4	9.6% 8	12.5% 9
Resistance ≥ 4 CLSI classes*	0.0% 0	7.1% 1	2.9% 1	0.0% 0	2.8% 1	0.0% 0	3.8% 4	2.7% 2	7.2% 6	9.7% 7
Resistance ≥ 5 CLSI classes*	0.0% 0	7.1% 1	2.9% 1	0.0% 0	2.8% 1	0.0% 0	2.9% 3	1.4% 1	4.8% 4	6.9% 5
At least ACSSuT <sup>†</sup>	0.0% 0	7.1% 1	2.9% 1	0.0% 0	2.8% 1	0.0% 0	1.9% 2	1.4% 1	3.6% 3	6.9% 5
At least ACT/S <sup>‡</sup>	0.0% 0	7.1% 1	2.9% 1	0.0% 0						
At least ACSSuTAuCx <sup>§</sup>	0.0% 0	2.4% 2	0.0% 0							
At least ceftriaxone and nalidixic acid resistant	0.0% 0									

\* CLSI: Clinical and Laboratory Standards Institute

† ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline

‡ ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole

§ ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone

## F. Specific Drug Resistance Phenotypes

**Table 24. Number and percentage of isolates with resistance to at least ACSSuT, ACSSuTAuCx, nalidixic acid, and ceftriaxone among the 20 most common non-typhoidal *Salmonella* serotypes isolated in NARMS, 2009**

Rank	Serotype	N	ACSSuT*		ACSSuTAuCx <sup>†</sup>		Nalidixic Acid		Ceftriaxone	
			n	(%)	n	(%)	n	(%)	n	(%)
1	Enteritidis	410	0	(0.0%)	0	(0.0%)	15	(38.5%)	0	(0.0%)
2	Typhimurium	371	72	(64.3%)	6	(20.0%)	8	(20.5%)	24	(32.0%)
3	Newport	236	15	(13.4%)	15	(50.0%)	0	(0.0%)	15	(20.0%)
4	Javiana	105	0	(0.0%)	0	(0.0%)	1	(2.6%)	1	(1.3%)
5	Heidelberg	86	3	(2.7%)	1	(3.3%)	0	(0.0%)	18	(24.0%)
6	14,[5],12:i:-	72	5	(4.5%)	0	(0.0%)	0	(0.0%)	2	(2.7%)
7	Oranienburg	64	0	(0.0%)	0	(0.0%)	0	(0.0%)	0	(0.0%)
8	Saintpaul	57	1	(0.9%)	0	(0.0%)	1	(2.6%)	0	(0.0%)
9	Montevideo	56	0	(0.0%)	0	(0.0%)	0	(0.0%)	0	(0.0%)
10	Braenderup	55	0	(0.0%)	0	(0.0%)	0	(0.0%)	0	(0.0%)
11	Infantis	44	2	(1.8%)	2	(6.7%)	1	(2.6%)	5	(6.7%)
12	Muenchen	42	0	(0.0%)	0	(0.0%)	0	(0.0%)	0	(0.0%)
13	Mississippi	28	1	(0.9%)	0	(0.0%)	0	(0.0%)	0	(0.0%)
14	Thompson	27	0	(0.0%)	0	(0.0%)	0	(0.0%)	0	(0.0%)
15	Agona	21	2	(1.8%)	2	(6.7%)	1	(2.6%)	2	(2.7%)
16	Bareilly	20	0	(0.0%)	0	(0.0%)	0	(0.0%)	0	(0.0%)
17	Litchfield	20	0	(0.0%)	0	(0.0%)	0	(0.0%)	0	(0.0%)
18	Paratyphi B var. L(+) tartrate+	20	2	(1.8%)	0	(0.0%)	0	(0.0%)	1	(1.3%)
19	Hadar	19	0	(0.0%)	0	(0.0%)	1	(2.6%)	0	(0.0%)
20	Poona	16	0	(0.0%)	0	(0.0%)	0	(0.0%)	0	(0.0%)
<b>Subtotal</b>		<b>1769</b>	<b>103</b>	<b>(92.0%)</b>	<b>26</b>	<b>(86.7%)</b>	<b>28</b>	<b>(71.8%)</b>	<b>68</b>	<b>(90.7%)</b>
	All other serotypes	364	5	(4.5%)	3	(10.0%)	8	(20.5%)	6	(8.0%)
	Unknown serotype	19	1	(0.9%)	1	(3.3%)	2	(5.1%)	1	(1.3%)
	Partially serotyped	20	2	(1.8%)	0	(0.0%)	1	(2.6%)	0	(0.0%)
	Rough/Nonmotile isolates	20	1	(0.9%)	0	(0.0%)	0	(0.0%)	0	(0.0%)
<b>Total</b>		<b>2192</b>	<b>112</b>	<b>(100.0%)</b>	<b>30</b>	<b>(100.0%)</b>	<b>39</b>	<b>(100.0%)</b>	<b>75</b>	<b>(100.0%)</b>

\* ACSSuT: at least resistant to ampicillin, chloramphenicol, streptomycin, sulfoxazole, tetracycline

<sup>†</sup> ACSSuTAuCx: at least resistant to ACSSuT, amoxicillin-clavulanic acid, and ceftriaxone

## Box 2. Four major multidrug-resistant patterns among non-typhoidal *Salmonella*


During 1996–2009, 3,243 (13.0%) of 24,903 non-typhoidal *Salmonella* isolates tested in NARMS were resistant to  $\geq 3$  classes of antimicrobial agents. Among the 3,243 isolates, we identified the 4 most common multidrug-resistant (MDR) patterns based on resistance to 7 of the 15 agents currently tested in NARMS: ampicillin (A), chloramphenicol (C), streptomycin (S), sulfonamide (Su), tetracycline (T), amoxicillin-clavulanic acid (Au), and ceftriaxone (Cx). Unlike MDR criteria used for tables in the rest of this report, which defined “at least ACSSuT” as resistant to at least A, C, S, Su, and T, we used mutually exclusive criteria in this section: ACSSuT was defined as resistant to A, C, S, Su, and T, not resistant to Au and Cx; ACSSuTAuCx as resistant to all 7 agents; ASSuT as resistant to A, S, Su, and T, not resistant to C, Au, and Cx; and SSuT as resistant to S, Su, and T, not resistant to A, C, Au, and Cx. Use of mutually exclusive criteria is important in monitoring major and emerging patterns, which may be driven by different resistance mechanisms.

ACSSuT, ACSSuTAuCx, ASSuT, and SSuT isolates accounted for 73.1% of the 3,243 isolates resistant to  $\geq 3$  classes: 1,323 (40.8%) were ACSSuT, 476 (14.7%) ACSSuTAuCx, 295 (9.1%) ASSuT, and 275 (8.5%) SSuT. Serotype Typhimurium accounted for 90.0% of ACSSuT and 74.6% of ASSuT isolates. Of the ACSSuTAuCx isolates, 67.0% were serotype Newport and 19.8% were serotype Typhimurium. More than half of SSuT isolates were serotypes Typhimurium (26.6%), Stanley (12.7%), Derby (10.2%), and Heidelberg (9.8%).

Figure 1 below shows the percentage of the 4 MDR patterns by year among all non-typhoidal *Salmonella* isolates tested from 1996 through 2009. ACSSuT declined from 8.2% in 1996 to 3.7% in 2009. ACSSuTAuCx, first detected in 1997, peaked at 3.4% in 2002 before declining to 1.4% in 2009. ASSuT was  $\leq 3.0\%$  and SSuT was  $\leq 1.7\%$  from 1996 through 2009.

Refer to Table 7 in the Results section of this report for the percentage of “at least ACSSuT” by year (2000–09) among non-typhoidal *Salmonella* isolates, which includes ACSSuT and ACSSuTAuCx. Since “at least ACSSuTAuCx” in Table 7 includes resistance to all 7 agents, percentages are the same as in Figure 1.

**Figure 1. Percentage of 4 major MDR patterns\* among non-typhoidal *Salmonella* isolates, by year, 1996-2009**



\*Four most common multidrug-resistant (MDR) patterns that include resistance to  $\geq 3$  antimicrobial classes and any of the following agents: ampicillin (A), chloramphenicol (C), streptomycin (S), sulfonamide (Su), tetracycline (T), amoxicillin-clavulanic acid (Au), and ceftriaxone (Cx).



**Table 26. Percentage and number of *Salmonella* ser. Typhi isolates resistant to antimicrobial agents, 2000–2009**

Year			2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	
Total Isolates			177	197	195	332	304	318	322	401	410	361	
Rank	CLSI <sup>†</sup> Antimicrobial Class	Antibiotic (Resistance breakpoint)											
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
		Gentamicin (MIC ≥ 16)	0	0	0	0	0	0	0	0	0	0	
		Streptomycin (MIC ≥ 64)	9.0%	20.3%	7.2%	14.5%	11.8%	13.2%	18.9%	15.7%	11.5%	10.5%	
	β-lactam / β-lactamase inhibitor combinations	Amoxicillin-Clavulanic Acid (MIC ≥ 32)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	0.2%	0.0%	0.3%	
		Cephems	Ceftiofur (MIC ≥ 8)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
	Penicillins	Ampicillin (MIC ≥ 32)	9.0%	20.3%	5.6%	16%	11.8%	13.2%	20.5%	17%	13.2%	12.2%	
		Quinolones	Ciprofloxacin (MIC ≥ 4)	0.0%	0.0%	0.0%	0.3%	0.0%	0.3%	0.9%	1.0%	0.0%	
			Nalidixic Acid (MIC ≥ 32)	22%	29.9%	23.6%	37.7%	41.8%	48.4%	54.7%	61.8%	59.0%	60.1%
				39	59	46	125	127	154	176	248	242	217
	II	Aminoglycosides	Kanamycin (MIC ≥ 64)	0.0%	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Cephems			Cefoxitin (MIC ≥ 32)	0.6%	0.5%	0.0%	0.0%	0.0%	0.0%	0.3%	0.5%	0.0%	
			Cephalothin (MIC ≥ 32)	1.1%	0.5%	1.5%	0.0%	Not Tested					
				2	1	3	0	0	0	0	0	0	
Folate pathway inhibitors		Sulfisoxazole (MIC ≥ 512)	11.3%	20.8%	6.2%	16.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
		Trimethoprim-Sulfamethoxazole (MIC ≥ 4)	9.0%	20.8%	6.7%	16.9%	13.2%	14.5%	20.8%	16.2%	12.7%	12.2%	
Phenicols		Chloramphenicol (MIC ≥ 32)	10.7%	20.8%	6.2%	16.6%	13.2%	13.2%	19.6%	15.7%	12.9%	11.4%	
			19	41	12	55	40	42	63	63	53	41	
Tetracyclines		Tetracycline (MIC ≥ 16)	9.6%	20.8%	6.7%	15.4%	8.9%	10.1%	8.4%	6.2%	4.6%	5.5%	
			17	41	13	51	27	32	27	25	19	20	

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.

**Table 27. Resistance patterns of *Salmonella* ser. Typhi isolates, 2000–2009**

Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates	177	197	195	332	304	318	323	401	410	361
	%	%	%	%	%	%	%	%	%	%
	n	n	n	n	n	n	n	n	n	n
No resistance detected	72.3%	58.9%	74.4%	56.6%	56.6%	48.1%	40.2%	35.7%	38.0%	37.7%
	128	116	145	188	172	153	130	143	156	136
Resistance ≥ 1 CLSI class*	27.7%	41.1%	25.6%	43.4%	43.4%	51.9%	59.8%	64.3%	62.0%	62.3%
	49	81	50	144	132	165	193	258	254	225
Resistance ≥ 2 CLSI classes*	10.7%	22.8%	7.2%	17.5%	13.2%	14.5%	21.7%	18.0%	14.4%	14.1%
	19	45	14	58	40	46	70	72	59	51
Resistance ≥ 3 CLSI classes*	9.6%	21.8%	6.7%	16.6%	12.8%	13.8%	20.7%	17.5%	13.4%	12.7%
	17	43	13	55	39	44	67	70	55	46
Resistance ≥ 4 CLSI classes*	9.0%	21.3%	6.2%	16.3%	12.5%	12.9%	19.2%	17.0%	12.9%	12.2%
	16	42	12	54	38	41	62	68	53	44
Resistance ≥ 5 CLSI classes*	7.9%	16.8%	5.6%	14.2%	11.8%	11.9%	16.7%	14.7%	10.7%	10.0%
	14	33	11	47	36	38	54	59	44	36
At least ACSSuT <sup>†</sup>	7.9%	16.8%	5.6%	12.7%	7.9%	9.1%	5.9%	3.7%	2.4%	2.5%
	14	33	11	42	24	29	19	15	10	9
At least ACT/S <sup>‡</sup>	9.0%	17.8%	5.6%	15.7%	11.8%	12.9%	18.6%	15.2%	12.2%	10.5%
	16	35	11	52	36	41	60	61	50	38
At least ACSSuTAuCx <sup>§</sup>	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	0	0	0	0	0	0	0	0	0	0
At least ceftriaxone and nalidixic acid resistant	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	0	0	0	0	0	0	0	0	0	0

\* CLSI: Clinical and Laboratory Standards Institute

† ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline

‡ ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole

§ ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone



**Table 30. Percentage and number of *Salmonella* ser. Paratyphi A, Paratyphi B, and Paratyphi C isolates resistant to antimicrobial agents, 2000–2009**

Year			2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	
Total Isolates			5	9	10	8	11	18	16	17	92	102	
Rank <sup>†</sup>	CLSI <sup>†</sup> Antimicrobial Class	Antibiotic (Resistance breakpoint)											
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
		Gentamicin (MIC ≥ 16)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
		Streptomycin (MIC ≥ 64)	20.0%	0.0%	10.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	1.0%
	β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid (MIC ≥ 32/16)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	0.0%
		Cephems											
	Cephems	Ceftiofur (MIC ≥ 8)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	0.0%
		Ceftriaxone (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	0.0%
	Penicillins	Ampicillin (MIC ≥ 32)	20.0%	0.0%	0.0%	12.5%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	1.0%
	Quinolones	Ciprofloxacin (MIC ≥ 4)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		Nalidixic acid (MIC ≥ 32)	40.0%	55.6%	40.0%	75.0%	72.7%	66.7%	50.0%	94.1%	85.9%	86.3%	
II	Aminoglycosides	Kanamycin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
		Cephems											
	Cephems	Cefoxitin (MIC ≥ 32)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	0.0%	
		Cephalothin (MIC ≥ 32)	0.0%	0.0%	0.0%	0.0%	Not Tested						
	Folate pathway inhibitors	Sulfamethoxazole/Sulfisoxazole <sup>‡</sup> (MIC ≥ 512)	20.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	1.0%
		Trimethoprim-sulfamethoxazole (MIC ≥ 4/76)	20.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.0%
	Phenicol	Chloramphenicol (MIC ≥ 32)	20.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	1.0%	
	Tetracyclines	Tetracycline (MIC ≥ 16)	0.0%	0.0%	10.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.2%	1.0%	

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.

**Table 31. Resistance patterns of *Salmonella* ser. Paratyphi A, Paratyphi B, and Paratyphi C isolates, 2000–2009**

Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates	5	9	10	8	11	18	16	17	92	102
	%	%	%	%	%	%	%	%	%	%
	n	n	n	n	n	n	n	n	n	n
No resistance detected	40.0%	44.4%	50.0%	12.5%	27.3%	33.3%	50.0%	5.9%	12.0%	12.7%
	2	4	5	1	3	6	8	1	11	13
Resistance ≥ 1 CLSI class*	60.0%	55.6%	50.0%	87.5%	72.7%	66.7%	50.0%	94.1%	88.0%	87.3%
	3	5	5	7	8	12	8	16	81	89
Resistance ≥ 2 CLSI classes*	20.0%	0.0%	10.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	1.0%
	1	0	1	0	0	0	0	0	1	1
Resistance ≥ 3 CLSI classes*	20.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	1.0%
	1	0	0	0	0	0	0	0	1	1
Resistance ≥ 4 CLSI classes*	20.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	1.0%
	1	0	0	0	0	0	0	0	1	1
Resistance ≥ 5 CLSI classes*	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	1.0%
	0	0	0	0	0	0	0	0	1	1
At least ACSSuT <sup>†</sup>	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	1.0%
	0	0	0	0	0	0	0	0	1	1
At least ACT/S <sup>‡</sup>	20.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.0%
	1	0	0	0	0	0	0	0	0	1
At least ACSSuTAuCx <sup>§</sup>	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	0.0%
	0	0	0	0	0	0	0	0	1	0
At least ceftriaxone and nalidixic acid resistant	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	0	0	0	0	0	0	0	0	0	0

\* CLSI: Clinical and Laboratory Standards Institute

† ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline

‡ ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole

§ ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone

### Box 3. Molecular characterization of Non-Typhi *Salmonella enterica* that show decreased susceptibility to extended-spectrum cephalosporins

Although most *Salmonella* infections are self-limited and treated symptomatically, antimicrobial therapy is necessary for the management of invasive infections. The recommended regimen used to include either amoxicillin or trimethoprim-sulphamethoxazole, but due to increased resistance levels to these drugs, current recommendations suggest using a fluoroquinolone, such as ciprofloxacin, or an extended-spectrum cephalosporin, such as ceftriaxone.

Among 4,236 isolates of non-typhi *Salmonella* (NTS) submitted to NARMS in 2005 and 2006, 175 (4.1%) displayed decreased susceptibility (MIC  $\geq$  2 mg/L) to the extended-spectrum cephalosporins ceftriaxone or ceftiofur. Among these, thirty different serotypes were represented and the three most prevalent serotypes were Newport (33.1%), Typhimurium (13.7%) and Heidelberg (13.1%).

Among the 175 isolates, 172 were available for molecular analysis. For each isolate, genomic DNA was prepared and the presence of  $\beta$ -lactamase genes investigated by polymerase chain reaction (PCR) amplification targeting six different genes: *bla*<sub>TEM</sub>, *bla*<sub>OXA</sub>, *bla*<sub>SHV</sub>, *bla*<sub>CTX-M</sub>, *bla*<sub>PSE</sub> and *bla*<sub>CMY</sub>.

One or more  $\beta$ -lactamase genes were detected in 139 (80.8%) isolates. The most prevalent resistance mechanisms were AmpC  $\beta$ -lactamase genes (*bla*<sub>CMY</sub>) which were identified in 133 (95.7%) of the 139  $\beta$ -lactamase-carrying isolates. The ceftriaxone MIC-values for the *bla*<sub>CMY</sub>-containing isolates ranged from 4 to 64 mg/L; all *bla*<sub>CMY</sub>-bearing isolates were thereby classified as ceftriaxone resistant according to current CLSI guidelines.

Other  $\beta$ -lactamase genes detected included eleven *bla*<sub>TEM-1</sub>, three *bla*<sub>PSE-1</sub>, two *bla*<sub>OXA-1</sub> and one *bla*<sub>CTX-M-15</sub>. The latter is an extended-spectrum  $\beta$ -lactamase (ESBL) that exhibits increased activity against cefotaxime and confers cross-resistance to the fourth generation cephalosporin cefepime. The *bla*<sub>CTX-M-15</sub> gene was found in an isolate of serotype Concord and is the second CTX-M-producing *Salmonella* identified in the NARMS human isolate collection (the first case was a CTX-M-5-producing *Salmonella* ser. Typhimurium isolated from a 3-month old child in 2003). The source of the CTX-M-15-producing *Salmonella* remains unknown, but it is likely that the infection was acquired abroad since the patient reported international travel to Ethiopia in conjunction with illness onset.

In conclusion, among NTS isolated from humans in 2005-2006, CMY  $\beta$ -lactamases were the predominant cause of decreased susceptibility and resistance to extended-spectrum cephalosporins. To limit further spread of these genes, prudent use of antimicrobial agents in both human and veterinary medicine will be crucial. Continued surveillance for cephalosporin-resistant bacteria among humans remains critical.

#### Box 4. Reduced azithromycin susceptibility in *Shigella sonnei*, United States

*Shigella* spp. are a major cause of gastroenteritis in the United States, transmitted most commonly by the fecal-oral route. It occurs most often in children 5 years old and younger in child care settings. While treatment with antimicrobial agents may shorten the duration of clinical symptoms for this usually self-limiting disease, emergence of antimicrobial resistance has recently made drug selection difficult. Previous drugs of choice for treatment of shigellosis were ampicillin and trimethoprim-sulfamethoxazole, but resistance to these drugs is high, especially in *Shigella sonnei*. Because of resistance to these agents, the macrolide azithromycin has been recommended by the American Academy of Pediatrics for treatment of shigellosis in children. Azithromycin resistance in *Shigella sonnei* is now being reported, but there are currently no CLSI criteria for interpretation of azithromycin susceptibility test results for *Shigella*. To explore azithromycin susceptibility in the United States, we determined MIC distributions for *Shigella sonnei* isolated from humans in the United States.

Azithromycin MICs were determined by broth microdilution for *Shigella sonnei* isolates from 11 recognized outbreaks in 10 states in 2006-2007 (n=56) and for those submitted routinely to NARMS in 2005 (the most recently completed year at the time, n=336) from 44 states. Five isolates collected from 1969-1974 (before approval of azithromycin) were also tested for historical perspective, but were not included in the MIC distribution analysis. Each isolate that demonstrated an azithromycin MIC > 64 mg/L was screened for the *mphA* gene by PCR, and the gene was sequenced to confirm positives.

The resulting distribution was log-normal and spanned three doubling dilution steps (4-16 mg/L) with an MIC<sub>50</sub> and MIC<sub>90</sub> of 8 mg/L. Five isolates collected from 1969-1974 exhibited azithromycin MICs of either 4 mg/L (n=1) or 8 mg/L (n=4). One outbreak isolate and two routine isolates showed MICs at least four-fold higher than the MIC<sub>90</sub> for the overall group of isolates; the outbreak isolate displayed an MIC of 256 mg/L and the routine isolates showed MICs of 256 and 128 mg/L. These isolates were PCR-positive for *mphA*, which encodes a macrolide-2'-phosphotransferase. In all three isolates, the gene was on a transferrable plasmid, with plasmid sizes ranging from 15-150kb.

Decreased azithromycin susceptibility for *Shigella sonnei* in the face of high levels of ampicillin and trimethoprim-sulfamethoxazole resistance is particularly worrisome for children because the remaining options for treatment are ceftriaxone, which is administered by injection and fluoroquinolones such as ciprofloxacin, which are not approved for use in children. Continued surveillance will be needed to examine antimicrobial use practices for *Shigella* infections and to determine whether azithromycin use leads to decreased susceptibility to the agent. Clinical outcome studies are needed to establish clinical breakpoints for azithromycin in treating *Shigella*.



Figure 21. Antimicrobial resistance pattern for *Shigella*, 2009




Table 34. Percentage and number of *Shigella* isolates resistant to antimicrobial agents, 2000–2009

Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	
Total Isolates	450	344	620	495	316	396	402	480	549	475	
Rank*	CLSI† Antimicrobial Class		Antibiotic (Resistance breakpoint)								
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
		Gentamicin (MIC ≥ 16)	0.2%	0.0%	0.2%	0.0%	0.0%	1.0%	0.2%	0.8%	0.4%
		Streptomycin (MIC ≥ 64)	57.1%	53.2%	54.4%	57.0%	59.8%	68.7%	60.7%	73.3%	80.7%
	β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clawulanic acid (MIC ≥ 32/16)	2.2%	4.4%	2.6%	1.4%	1.6%	1.0%	1.5%	0.4%	3.3%
		Cephems	Ceftiofur (MIC ≥ 8)	0.0%	0.0%	0.2%	0.2%	0.3%	0.5%	0.2%	0.0%
	Penicillins	Ceftriaxone (MIC ≥ 64)	0.0%	0.0%	0.2%	0.2%	0.3%	0.5%	0.2%	0.0%	0.6%
		Ampicillin (MIC ≥ 32)	79.1%	79.7%	76.6%	79.4%	77.5%	70.7%	62.4%	63.8%	62.5%
	Quinolones	Ciprofloxacin (MIC ≥ 4)	356	274	475	393	245	280	251	306	343
		Nalidixic acid (MIC ≥ 32)	0.0%	0.3%	0.0%	0.0%	0.0%	0.0%	0.2%	0.2%	0.7%
	II	Aminoglycosides	Kanamycin (MIC ≥ 64)	0.9%	1.7%	1.6%	1.0%	1.6%	1.5%	3.5%	1.7%
Cephems			Cefoxitin (MIC ≥ 32)	4	6	10	5	5	6	14	8
Folate pathway inhibitors		Cephalothin (MIC ≥ 32)	1.3%	0.6%	0.8%	0.4%	0.0%	0.8%	0.0%	0.2%	0.5%
		Sulfamethoxazole/Sulfisoxazole‡ (MIC ≥ 512)	6	2	5	2	0	3	0	1	3
Phenicols		Cefoxitin (MIC ≥ 32)	0.2%	1.2%	0.3%	0.0%	0.3%	0.3%	0.0%	0.0%	0.0%
		Cephalothin (MIC ≥ 32)	8.0%	9.0%	6.6%	9.3%	Not Tested				
Tetracyclines		Sulfamethoxazole/Sulfisoxazole‡ (MIC ≥ 4/76)	55.8%	56.4%	31.8%	33.9%	52.5%	57.6%	40.3%	25.8%	28.6%
		Trimethoprim-sulfamethoxazole (MIC ≥ 4/76)	251	194	197	168	166	228	162	124	157
Tetracyclines		Chloramphenicol (MIC ≥ 32)	52.9%	46.8%	37.3%	38.6%	46.8%	53.3%	46.0%	25.8%	31.3%
		Tetracycline (MIC ≥ 16)	238	161	231	191	148	211	185	124	172
Tetracyclines	Chloramphenicol (MIC ≥ 32)	14.0%	21.5%	7.6%	8.5%	15.2%	10.9%	10.9%	8.3%	6.9%	
	Tetracycline (MIC ≥ 16)	63	74	47	42	48	43	44	40	38	
Tetracyclines	Tetracycline (MIC ≥ 16)	44.9%	59.3%	30.6%	29.1%	49.4%	38.4%	34.6%	25.6%	24.2%	
	Tetracycline (MIC ≥ 16)	202	204	190	144	156	152	139	123	133	

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.

**Table 35. Resistance patterns of *Shigella* isolates, 2000–2009**

Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
<b>Total Isolates</b>	<b>450</b>	<b>344</b>	<b>620</b>	<b>495</b>	<b>316</b>	<b>396</b>	<b>402</b>	<b>480</b>	<b>549</b>	<b>475</b>
	% n									
No resistance detected	7.3% 33	4.9% 17	8.2% 51	8.5% 42	4.7% 15	4.5% 18	6.5% 26	7.1% 34	4.4% 24	4.0% 19
Resistance ≥ 1 CLSI class*	92.7% 417	95.1% 327	91.8% 569	91.5% 453	95.3% 301	95.5% 378	93.5% 376	92.9% 446	95.6% 525	96.0% 456
Resistance ≥ 2 CLSI classes*	64.7% 291	68.6% 236	55.2% 342	57.8% 286	64.2% 203	71.7% 284	64.7% 260	65.4% 314	68.3% 375	67.8% 322
Resistance ≥ 3 CLSI classes*	61.3% 276	59.9% 206	41.5% 257	40.2% 199	59.2% 187	58.6% 232	43.8% 176	27.7% 133	35.2% 193	36.4% 173
Resistance ≥ 4 CLSI classes*	31.8% 143	45.3% 156	24.4% 151	24.8% 123	32.9% 104	19.4% 77	15.4% 62	11.7% 56	10.4% 57	13.3% 63
Resistance ≥ 5 CLSI classes*	6.4% 29	7.6% 26	2.7% 17	3.6% 18	7.0% 22	4.8% 19	5.2% 21	4.6% 22	2.7% 15	6.3% 30
At least ACSSuT†	5.6% 25	6.4% 22	1.8% 11	3.2% 16	6.0% 19	4.0% 16	5.0% 20	3.8% 18	2.2% 12	5.9% 28
At least ACT/S‡	6.9% 31	7.0% 24	2.7% 17	3.6% 18	6.6% 21	6.3% 25	6.0% 24	4.0% 19	2.9% 16	6.7% 32
At least AT/S§	44.4% 200	37.5% 129	29.8% 185	33.7% 167	34.5% 109	35.6% 141	26.6% 107	12.9% 62	16.0% 88	17.5% 83
At least ANT/S¶	0.0% 0	0.6% 2	0.3% 2	0.8% 4	0.6% 2	0.5% 2	0.5% 2	0.8% 4	0.0% 0	0.2% 1
At least ACSSuTAuCx**	0.0% 0									
At least ceftriaxone and nalidixic acid resistant	0.0% 0	0.0% 0	0.0% 0	0.2% 1	0.3% 1	0.3% 1	0.2% 1	0.0% 0	0.0% 0	0.0% 0

\* CLSI: Clinical and Laboratory Standards Institute

† ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline

‡ ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole

§ AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole

¶ ANT/S: resistance to AT/S, nalidixic acid

\*\* ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone

**Table 36. Minimum inhibitory concentrations (MICs) and resistance of *Shigella sonnei* isolates to antimicrobial agents, 2009 (N=410)**

Rank*	CLSI† Antimicrobial Class	Antimicrobial Agent	% of isolates			Percent of all isolates with MIC (µg/mL)**																
			%‡	%R§	[95% CI]¶	0.015	0.03	0.06	0.125	0.25	0.50	1	2	4	8	16	32	64	128	256	512	
I	Aminoglycosides	Amikacin	0.0	0.0	[0.0 - 0.9]						0.5	2.0	35.1	59.5	2.9							
		Gentamicin	0.0	0.7	[0.1 - 2.1]					1.5	14.9	78.0	4.4	0.5			0.2	0.5				
		Streptomycin	N/A	91.5	[88.3 - 94.0]													8.5	48.3	43.2		
	β-lactam / β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid	14.6	2.0	[0.8 - 3.8]							2.4	2.7	50.5	27.8	14.6	1.5	0.5				
		Cephems								5.6	83.4	8.3	2.2									
		Ceftriaxone	0.0	0.5	[0.05 - 1.7]																	
		Ceftriaxone	0.0	0.5	[0.05 - 1.7]																	
		Penicillins																				
		Ampicillin	0.0	43.2	[38.3 - 48.1]								4.4	47.8	4.1	0.5			0.2	42.9		
		Quinolones																				
	Ciprofloxacin	0.0	0.0	[0.0 - 0.9]	98.0	0.2	1.0	0.2	0.5													
	Nalidixic acid	N/A	1.7	[0.7 - 3.5]							4.6	83.7	8.3	1.7								
II	Aminoglycosides	Kanamycin	0.0	0.2	[0.00 - 1.3]											99.5	0.2				0.2	
	Cephems	Cefoxitin	0.0	0.7	[0.1 - 2.1]							0.5	18.8	73.7	5.9	0.5		0.5	0.2			
	Folate pathway inhibitors	Sulfisoxazole	N/A	23.9	[19.9 - 28.3]												65.6	7.1	2.2	1.2		
		Trimethoprim-sulfamethoxazole	N/A	36.1	[31.4 - 41.0]																	23.9
		Phenicol	Chloramphenicol	0.0	1.2	[0.4 - 2.8]																1.2
		Tetracyclines	Tetracycline	0.5	20.7	[16.9 - 25.0]																

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Percent of isolates with intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists

§ Percent of isolates that were resistant

¶ The 95% confidence intervals (CI) for percent resistant (%R) were calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method. The 95% CI is presented to summarize uncertainty in the observed resistance (%R).

\*\* The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the percentages of isolates with MICs equal to or less than the low est tested concentration. CLSI breakpoints were used when available.

Figure 22. Antimicrobial resistance pattern for *Shigella sonnei*, 2009




Table 37. Percentage and number of *Shigella sonnei* isolates resistant to antimicrobial agents, 2000–2009

Year			2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates			366	239	536	434	241	340	321	414	496	410
Rank*	CLSI† Antimicrobial Class	Antibiotic (Resistance breakpoint)										
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		Gentamicin (MIC ≥ 16)	0.3%	0.0%	0.0%	0.0%	0.0%	1.2%	0.0%	1.0%	0.4%	0.7%
		Streptomycin (MIC ≥ 64)	56.0%	54.0%	55.4%	56.5%	56.8%	70.3%	61.7%	76.8%	82.5%	91.5%
	β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid (MIC ≥ 32/16)	1.9%	4.6%	2.2%	1.4%	1.7%	1.2%	1.9%	0.5%	3.2%	2.0%
			7	11	12	6	4	4	6	2	16	8
	Cephems	Ceftiofur (MIC ≥ 8)	0.0%	0.0%	0.0%	0.0%	0.4%	0.6%	0.0%	0.0%	0.0%	0.5%
		Ceftriaxone (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.4%	0.6%	0.0%	0.0%	0.0%	0.5%
	Penicillins	Ampicillin (MIC ≥ 32)	80.6%	82.8%	77.6%	79.7%	79.3%	70.6%	62.6%	64.0%	61.5%	43.2%
			295	198	416	346	191	240	201	265	305	177
	Quinolones	Ciprofloxacin (MIC ≥ 4)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%
Nalidixic acid (MIC ≥ 32)		1.1%	0.8%	1.5%	0.5%	1.7%	1.2%	2.8%	1.2%	1.6%	1.7%	
II	Aminoglycosides	Kanamycin (MIC ≥ 64)	1.6%	0.4%	0.4%	0.0%	0.0%	0.0%	0.0%	0.2%	0.6%	0.2%
			6	1	2	0	0	0	0	1	3	1
	Cephems	Cefoxitin (MIC ≥ 32)	0.3%	1.7%	0.4%	0.0%	0.4%	0.3%	0.0%	0.0%	0.0%	0.7%
		Cephalothin (MIC ≥ 32)	8.7%	12.6%	7.3%	10.1%	Not Tested					
	Folate pathway inhibitors	Sulfamethoxazole/Sulfisoxazole‡ (MIC ≥ 512)	56.0%	54.4%	29.9%	31.3%	49.0%	57.9%	33.3%	20.0%	25.0%	23.9%
			205	130	160	136	118	197	107	83	124	98
		Trimethoprim-sulfamethoxazole (MIC ≥ 4/76)	54.9%	50.6%	37.9%	38.5%	46.9%	55.0%	42.7%	22.0%	29.4%	36.1%
			201	121	203	167	113	187	137	91	146	148
	Phenicol	Chloramphenicol (MIC ≥ 32)	2.7%	1.3%	0.2%	1.2%	2.5%	2.4%	0.9%	1.2%	1.0%	1.2%
			10	3	1	5	6	8	3	5	5	5
Tetracyclines	Tetracycline (MIC ≥ 16)	34.4%	44.8%	23.5%	22.1%	36.1%	29.4%	22.7%	16.2%	17.3%	20.7%	
		126	107	126	96	87	100	73	67	86	85	

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.

**Table 38. Resistance patterns of *Shigella sonnei* isolates, 2000–2009**

Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
<b>Total Isolates</b>	<b>366</b>	<b>239</b>	<b>536</b>	<b>434</b>	<b>241</b>	<b>340</b>	<b>321</b>	<b>414</b>	<b>496</b>	<b>410</b>
	%	%	%	%	%	%	%	%	%	%
	n	n	n	n	n	n	n	n	n	n
No resistance detected	7.7%	5.4%	7.1%	8.5%	5.4%	4.4%	6.2%	6.8%	4.4%	3.7%
	28	13	38	37	13	15	20	28	22	15
Resistance ≥ 1 CLSI class*	92.3%	94.6%	92.9%	91.5%	94.6%	95.6%	93.8%	93.2%	95.6%	96.3%
	338	226	498	397	228	325	301	386	474	395
Resistance ≥ 2 CLSI classes*	60.7%	59.8%	51.9%	54.1%	56.4%	70.3%	59.8%	63.0%	65.7%	65.1%
	222	143	278	235	136	239	192	261	326	267
Resistance ≥ 3 CLSI classes*	56.8%	51.5%	36.4%	35.3%	50.6%	55.3%	35.8%	21.3%	29.8%	29.8%
	208	123	195	153	122	188	115	88	148	122
Resistance ≥ 4 CLSI classes*	25.4%	37.7%	19.8%	20.5%	25.7%	12.4%	8.1%	5.1%	5.6%	5.9%
	93	90	106	89	62	42	26	21	28	24
Resistance ≥ 5 CLSI classes*	1.4%	0.0%	0.6%	0.5%	0.8%	0.9%	0.0%	1.2%	0.4%	0.2%
	5	0	3	2	2	3	0	5	2	1
At least ACSSuT†	0.8%	0.0%	0.0%	0.2%	0.0%	0.3%	0.0%	0.5%	0.2%	0.0%
	3	0	0	1	0	1	0	2	1	0
At least ACT/S‡	1.9%	0.8%	0.2%	0.9%	1.7%	2.4%	0.9%	0.5%	0.8%	1.0%
	7	2	1	4	4	8	3	2	4	4
At least AT/S§	46.2%	41.0%	30.2%	33.6%	35.3%	35.6%	22.7%	9.4%	14.3%	12.2%
	169	98	162	146	85	121	73	39	71	50
At least ANT/S¶	0.0%	0.0%	0.2%	0.2%	0.8%	0.3%	0.0%	0.7%	0.0%	0.0%
	0	0	1	1	2	1	0	3	0	0
At least ACSSuTAuCx**	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	0	0	0	0	0	0	0	0	0	0
At least ceftriaxone and nalidixic acid resistant	0.0%	0.0%	0.0%	0.0%	0.4%	0.3%	0.0%	0.0%	0.0%	0.0%
	0	0	0	0	1	1	0	0	0	0

\* CLSI: Clinical and Laboratory Standards Institute

† ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline

‡ ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole

§ AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole

¶ ANT/S: resistance to AT/S, nalidixic acid

\*\* ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone

**Table 39. Minimum inhibitory concentrations and resistance of *Shigella flexneri* isolates to antimicrobial agents, 2009 (N=57)**

Rank*	CLSI† Antimicrobial Class	Antimicrobial Agent	% of isolates			Percent of all isolates with MIC (µg/mL)**												
			%‡	%R§	[95% CI]¶	0.015	0.03	0.06	0.125	0.25	0.50	1	2	4	8	16	32	64
I	Aminoglycosides	Amikacin	0.0	0.0	[0.0 - 6.3]	[Shaded area: 0.015-0.50; 1.8, 22.8, 59.6, 14.0, 1.8]												
		Gentamicin	0.0	0.0	[0.0 - 6.3]	[Shaded area: 0.015-0.50; 1.8, 24.6, 68.4, 5.3]												
		Streptomycin	NA	73.7	[60.3 - 84.5]	[Shaded area: 0.015-0.50; 26.3, 12.3, 61.4]												
	β-lactam / β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid	54.4	3.5	[0.4 - 12.1]	[Shaded area: 0.015-0.50; 1.8, 19.3, 8.8, 12.3, 54.4, 3.5]												
		Cephems	Ceftiofur	0.0	1.8	[0.02 - 9.4]	[Shaded area: 0.015-0.50; 38.6, 47.4, 8.8, 3.5]											
	Penicillins	Ceftriaxone		0.0	1.8	[0.02 - 9.4]	[Shaded area: 0.015-0.50; 98.2]											
		Quinolones	Ampicillin	0.0	70.2	[56.6 - 81.6]	[Shaded area: 0.015-0.50; 24.6, 5.3]											
	Ciprofloxacin		0.0	3.5	[0.4 - 12.1]	[Shaded area: 0.015-0.50; 94.7, 1.8]												
		Nalidixic acid	NA	3.5	[0.4 - 12.1]	[Shaded area: 0.015-0.50; 1.8, 71.9, 19.3, 3.5]												
II	Aminoglycosides	Kanamycin	0.0	1.8	[0.02 - 9.4]	[Shaded area: 0.015-0.50; 98.2]												
	Cephems	Cefoxitin	0.0	0.0	[0.0 - 6.3]	[Shaded area: 0.015-0.50; 3.5, 52.6, 40.4, 3.5]												
	Folate pathway inhibitors	Sulfisoxazole	NA	73.7	[60.3 - 84.5]	[Shaded area: 0.015-0.50; 26.3, 3.5, 1.8]												
		Trimethoprim-sulfamethoxazole	NA	68.4	[54.8 - 80.1]	[Shaded area: 0.015-0.50; 68.4]												
	Phenicol	Chloramphenicol	0.0	66.7	[52.9 - 78.6]	[Shaded area: 0.015-0.50; 29.8, 1.8, 1.8]												
Tetracyclines	Tetracycline	1.8	87.7	[76.3 - 94.9]	[Shaded area: 0.015-0.50; 10.5, 1.8, 1.8, 5.3, 80.7]													

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Percent of isolates with intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists

§ Percent of isolates that were resistant

¶ The 95% confidence intervals (CI) for percent resistant (%R) were calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method. The 95% CI is presented to summarize uncertainty in the observed resistance (R%).

\*\* The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the percentages of isolates with MICs equal to or less than the low est tested concentration. CLSI breakpoints were used when available.

Figure 23. Antimicrobial resistance pattern for *Shigella flexneri*, 2009




Table 40. Percentage and number of *Shigella flexneri* isolates resistant to antimicrobial agents, 2000–2009

Year			2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates			75	91	73	51	62	52	74	61	45	57
Rank*	CLSI† Antimicrobial Class	Antibiotic (Resistance breakpoint)										
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		Gentamicin (MIC ≥ 16)	0.0%	0.0%	1.4%	0.0%	0.0%	0.0%	1.4%	0.0%	0.0%	0.0%
		Streptomycin (MIC ≥ 64)	61.3%	47.3%	43.8%	60.8%	71.0%	57.7%	58.1%	52.5%	62.2%	73.7%
	β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clawulanic acid (MIC ≥ 32/16)	4.0%	4.4%	5.5%	2.0%	1.6%	0.0%	0.0%	0.0%	4.4%	3.5%
			3	4	4	1	1	0	0	0	2	2
	Cephems	Ceftiofur (MIC ≥ 8)	0.0%	0.0%	1.4%	2.0%	0.0%	0.0%	1.4%	0.0%	0.0%	1.8%
		Ceftriaxone (MIC ≥ 64)	0.0%	0.0%	1.4%	2.0%	0.0%	0.0%	1.4%	0.0%	0.0%	1.8%
	Penicillins	Ampicillin (MIC ≥ 32)	77.3%	72.5%	75.3%	84.3%	80.6%	75.0%	63.5%	63.9%	75.6%	70.2%
			58	66	55	43	50	39	47	39	34	40
	Quinolones	Ciprofloxacin (MIC ≥ 4)	0.0%	1.1%	0.0%	0.0%	0.0%	0.0%	1.4%	1.6%	2.2%	3.5%
Nalidixic acid (MIC ≥ 32)		0.0%	3.3%	2.7%	5.9%	1.6%	3.8%	5.4%	4.9%	2.2%	3.5%	
		0	3	2	3	1	2	4	3	1	2	
		0	0	1	1	0	0	1	0	0	1	
II	Aminoglycosides	Kanamycin (MIC ≥ 64)	0.0%	1.1%	4.1%	3.9%	0.0%	3.8%	0.0%	0.0%	0.0%	1.8%
			0	1	3	2	0	2	0	0	0	1
	Cephems	Cefoxitin (MIC ≥ 32)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		Cephalothin (MIC ≥ 32)	2.7%	1.1%	2.7%	3.9%	Not Tested					
	Folate pathway inhibitors	Sulfamethoxazole/Sulfisoxazole‡ (MIC ≥ 512)	53.3%	57.1%	41.1%	52.9%	66.1%	55.8%	68.9%	62.3%	62.2%	73.7%
			40	52	30	27	41	29	51	38	28	42
		Trimethoprim-sulfamethoxazole (MIC ≥ 4/76)	42.7%	34.1%	28.8%	39.2%	46.8%	44.2%	59.5%	49.2%	48.9%	68.4%
			32	31	21	20	29	23	44	30	22	39
	Phenicol	Chloramphenicol (MIC ≥ 32)	69.3%	74.7%	63.0%	68.6%	61.3%	65.4%	54.1%	55.7%	68.9%	66.7%
			52	68	46	35	38	34	40	34	31	38
Tetracyclines	Tetracycline (MIC ≥ 16)	92.0%	94.5%	78.1%	82.4%	95.2%	94.2%	83.8%	83.6%	86.7%	87.7%	
		69	86	57	42	59	49	62	51	39	50	

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.

**Table 41. Resistance patterns of *Shigella flexneri* isolates, 2000–2009**

Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
<b>Total Isolates</b>	<b>75</b>	<b>91</b>	<b>73</b>	<b>51</b>	<b>62</b>	<b>52</b>	<b>74</b>	<b>61</b>	<b>45</b>	<b>57</b>
	%	%	%	%	%	%	%	%	%	%
	n	n	n	n	n	n	n	n	n	n
No resistance detected	4.0%	3.3%	15.1%	7.8%	0.0%	5.8%	5.4%	9.8%	4.4%	5.3%
	3	3	11	4	0	3	4	6	2	3
Resistance ≥ 1 CLSI class*	96.0%	96.7%	84.9%	92.2%	100.0%	94.2%	94.6%	90.2%	95.6%	94.7%
	72	88	62	47	62	49	70	55	43	54
Resistance ≥ 2 CLSI classes*	82.7%	89.0%	76.7%	86.3%	93.5%	80.8%	85.1%	80.3%	93.3%	86.0%
	62	81	56	44	58	42	63	49	42	49
Resistance ≥ 3 CLSI classes*	81.3%	79.1%	75.3%	80.4%	90.3%	78.8%	75.7%	68.9%	84.4%	82.5%
	61	72	55	41	56	41	56	42	38	47
Resistance ≥ 4 CLSI classes*	64.0%	62.6%	57.5%	62.7%	64.5%	65.4%	47.3%	55.7%	57.8%	63.2%
	48	57	42	32	40	34	35	34	26	36
Resistance ≥ 5 CLSI classes*	32.0%	25.3%	19.2%	31.4%	29.0%	30.8%	28.4%	27.9%	28.9%	49.1%
	24	23	14	16	18	16	21	17	13	28
At least ACSSuT <sup>†</sup>	29.3%	22.0%	15.1%	29.4%	27.4%	28.8%	27.0%	26.2%	24.4%	47.4%
	22	20	11	15	17	15	20	16	11	27
At least ACT/S <sup>‡</sup>	32.0%	23.1%	21.9%	27.5%	24.2%	32.7%	28.4%	26.2%	26.7%	47.4%
	24	21	16	14	15	17	21	16	12	27
At least AT/S <sup>§</sup>	38.7%	25.3%	27.4%	37.3%	35.5%	38.5%	43.2%	36.1%	33.3%	52.6%
	29	23	20	19	22	20	32	22	15	30
At least ANT/S <sup>¶</sup>	0.0%	1.1%	1.4%	5.9%	0.0%	1.9%	2.7%	1.6%	0.0%	1.8%
	0	1	1	3	0	1	2	1	0	1
At least ACSSuTAuCx <sup>**</sup>	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	0	0	0	0	0	0	0	0	0	0
At least ceftriaxone and nalidixic acid resistant	0.0%	0.0%	0.0%	2.0%	0.0%	0.0%	1.4%	0.0%	0.0%	0.0%
	0	0	0	1	0	0	1	0	0	0

\* CLSI: Clinical and Laboratory Standards Institute

† ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline

‡ ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole

§ AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole

¶ ANT/S: resistance to AT/S, nalidixic acid

\*\* ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone



**Table 43. Percentage and number of *Escherichia coli* O157 isolates resistant to antimicrobial agents, 2000–2009**

Year			2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates			407	277	399	158	169	194	233	190	159	188
Rank*	CLSI† Antimicrobial Class	Antibiotic (Resistance breakpoint)										
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		Gentamicin (MIC ≥ 16)	0.5%	0.4%	0.0%	0.0%	0.6%	0.5%	0.0%	0.0%	1.3%	0.5%
		Streptomycin (MIC ≥ 64)	5.2%	1.8%	2.3%	1.9%	1.8%	2.1%	2.6%	2.1%	1.9%	4.8%
	β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid (MIC ≥ 32/16)	1.0%	0.7%	0.0%	1.3%	0.0%	0.0%	1.3%	0.5%	0.6%	0.5%
		Cephems										
	Cephems	Ceftiofur (MIC ≥ 8)	1.0%	1.1%	0.0%	1.3%	0.0%	0.0%	1.3%	0.0%	0.6%	0.0%
		Ceftriaxone (MIC ≥ 64)	1.0%	0.7%	0.0%	1.3%	0.0%	0.0%	1.3%	0.0%	0.6%	0.0%
	Penicillins	Ampicillin (MIC ≥ 32)	2.7%	2.2%	1.5%	3.2%	1.2%	4.1%	2.6%	2.1%	3.8%	4.3%
		Quinolones										
	Quinolones	Ciprofloxacin (MIC ≥ 4)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.4%	0.5%	0.0%	0.5%
Nalidixic acid (MIC ≥ 32)		0.5%	1.1%	1.0%	0.6%	1.8%	1.5%	2.1%	2.1%	1.3%	2.1%	
II	Aminoglycosides	Kanamycin (MIC ≥ 64)	1.0%	0.0%	0.5%	0.0%	0.0%	0.5%	0.4%	0.0%	0.0%	0.5%
		Cephems										
	Cephems	Cefoxitin (MIC ≥ 32)	1.0%	0.7%	0.0%	1.3%	0.6%	0.0%	1.3%	0.0%	1.3%	0.5%
		Cephalothin (MIC ≥ 32)	1.2%	1.4%	1.5%	3.2%	Not Tested					
	Folate pathway inhibitors	Sulfamethoxazole/Sulfisoxazole‡ (MIC ≥ 5/12)	5.9%	5.1%	3.5%	3.8%	1.8%	6.7%	3.0%	2.6%	3.1%	6.4%
		Trimethoprim-sulfamethoxazole (MIC ≥ 4/76)	0.7%	0.7%	0.5%	0.6%	0.0%	0.5%	0.4%	1.1%	1.3%	4.3%
	Phenicol	Chloramphenicol (MIC ≥ 32)	3.7%	1.4%	1.3%	1.3%	0.6%	1.0%	1.3%	0.5%	0.6%	1.1%
		Tetracyclines										
	Tetracyclines	Tetracycline (MIC ≥ 16)	7.1%	5.4%	3.0%	5.7%	1.8%	8.8%	4.7%	4.7%	1.9%	7.4%

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.

**Table 44. Resistance patterns of *Escherichia coli* O157 isolates, 2000–2009**

Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates	407	277	399	158	169	194	233	190	159	188
	%	%	%	%	%	%	%	%	%	%
	n	n	n	n	n	n	n	n	n	n
No resistance detected	90.4%	91.3%	94.0%	90.5%	94.7%	87.6%	91.8%	92.1%	91.8%	89.9%
	368	253	375	143	160	170	214	175	146	169
Resistance ≥ 1 CLSI class*	9.6%	8.7%	6.0%	9.5%	5.3%	12.4%	8.2%	7.9%	8.2%	10.1%
	39	24	24	15	9	24	19	15	13	19
Resistance ≥ 2 CLSI classes*	6.6%	5.4%	3.8%	5.1%	2.4%	6.7%	4.7%	3.2%	3.1%	7.4%
	27	15	15	8	4	13	11	6	5	14
Resistance ≥ 3 CLSI classes*	4.7%	2.2%	2.0%	3.2%	1.2%	5.2%	3.4%	2.1%	2.5%	5.9%
	19	6	8	5	2	10	8	4	4	11
Resistance ≥ 4 CLSI classes*	3.4%	1.4%	0.8%	1.3%	0.6%	1.0%	2.1%	1.1%	1.3%	4.3%
	14	4	3	2	1	2	5	2	2	8
Resistance ≥ 5 CLSI classes*	1.2%	0.4%	0.0%	0.0%	0.0%	0.0%	0.9%	0.5%	0.0%	0.5%
	5	1	0	0	0	0	2	1	0	1
At least ACSSuT†	1.2%	0.4%	0.0%	0.0%	0.0%	0.0%	0.9%	0.0%	0.0%	0.0%
	5	1	0	0	0	0	2	0	0	0
At least ACT/S‡	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%
	1	0	0	0	0	0	0	0	1	0
At least ACSSuTAuCx§	1.0%	0.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	4	1	0	0	0	0	0	0	0	0
At least ceftriaxone and nalidixic acid resistant	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.4%	0.0%	0.0%	0.0%
	0	0	0	0	0	0	1	0	0	0

\* CLSI: Clinical and Laboratory Standards Institute

† ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline

‡ ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole

§ ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone



**Table 47. Percentage and number of *Campylobacter* isolates resistant to antimicrobial agents, 2000–2009**

Year			2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates			324	384	354	328	347	890	816	1100	1159	1502
Rank <sup>*</sup>	CLSI <sup>†</sup> Antimicrobial Class	Antibiotic (Resistance breakpoint)										
I	Aminoglycosides	Gentamicin (MIC ≥ 8)	0.3% 1	0.0% 0	0.0% 0	0.3% 1	0.3% 1	0.7% 6	0.1% 1	0.6% 7	1.1% 13	0.9% 13
		Ketolides	Not Tested	1.0% 9	1.6% 13	1.5% 16	2.5% 29	1.5% 22				
	Macrolides	Azithromycin (MIC ≥ 8)	1.9% 6	2.1% 8	2.0% 7	0.9% 3	0.6% 2	1.9% 17	1.7% 14	2.0% 22	3.0% 35	1.7% 25
		Erythromycin (MIC ≥ 32)	1.2% 4	2.1% 8	1.4% 5	0.9% 3	0.3% 1	1.8% 16	1.7% 14	2.0% 22	3.0% 35	1.7% 25
	Quinolones	Ciprofloxacin (MIC ≥ 4)	14.8% 48	19.5% 75	20.1% 71	17.7% 58	19.0% 66	21.7% 193	19.6% 160	26.0% 286	23.0% 267	22.9% 344
		Nalidixic acid (MIC ≥ 64)	16.7% 54	20.3% 78	20.6% 73	18.9% 62	19.6% 68	22.4% 199	20.1% 164	26.5% 291	23.6% 273	23.2% 348
II	Phenicol	Chloramphenicol (MIC ≥ 32)	0.0% 0	0.3% 1	0.3% 1	0.0% 0	1.4% 5	Not Tested				
		Florfenicol <sup>‡</sup> Susceptible breakpoint: (MIC ≤ 4)	Not Tested	0.6% 5	0.0% 0	0.0% 0	0.5% 6	0.5% 8				
	Tetracyclines	Tetracycline (MIC ≥ 16)	38.3% 124	40.9% 157	41.2% 146	38.4% 126	46.1% 160	40.6% 361	46.0% 375	44.4% 488	43.7% 507	43.5% 653
III	Lincosamides	Clindamycin (MIC ≥ 8)	0.9% 3	2.1% 8	2.0% 7	0.6% 2	2.0% 7	1.5% 13	2.0% 16	1.7% 19	2.8% 32	1.4% 21

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important; Rank 3, Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Only a susceptible breakpoint (≤ 4 µg/ml) has been established. In this report, isolates with an MIC ≥ 8 µg/ml are categorized as resistant

**Table 48. Resistance patterns of *Campylobacter* isolates, 2000–2009**

Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates	324	384	354	328	347	890	816	1100	1159	1502
	% n									
No resistance detected	52.2% 169	49.2% 189	48.3% 171	50.9% 167	46.1% 160	48.4% 431	43.9% 358	45.2% 497	45.8% 531	46.4% 697
Resistance ≥ 1 CLSI class*	47.8% 155	50.8% 195	51.7% 183	49.1% 161	53.9% 187	51.6% 459	56.1% 458	54.8% 603	54.2% 628	53.6% 805
Resistance ≥ 2 CLSI classes*	8.0% 26	13.3% 51	12.7% 45	8.5% 28	14.1% 49	13.6% 121	12.0% 98	17.5% 192	15.6% 181	13.8% 207
Resistance ≥ 3 CLSI classes*	0.9% 3	1.6% 6	1.1% 4	0.9% 3	1.2% 4	1.5% 13	1.5% 12	1.7% 19	2.5% 29	1.6% 24
Resistance ≥ 4 CLSI classes*	0.3% 1	0.3% 1	0.0% 0	0.3% 1	0.3% 1	0.3% 3	0.5% 4	0.9% 10	1.1% 13	1.0% 15
Resistance ≥ 5 CLSI classes*	0.0% 0	0.3% 3	0.3% 4							


\* CLSI: Clinical and Laboratory Standards Institute

**Table 49. Minimum inhibitory concentrations (MICs) and resistance of *Campylobacter jejuni* isolates to antimicrobial agents, 2009 (N=1355)**

Rank*	CLSI† Antimicrobial Class	Antimicrobial Agent	% of isolates			Percent of all isolates with MIC (µg/mL)**														
			%‡	%R§	[95% CI]¶	0.015	0.03	0.06	0.125	0.25	0.50	1	2	4	8	16	32	64	128	256
I	Amnoglycosides	Gentamicin	0.0	0.7	[0.3 - 1.3]	[Shaded area: 0.015-0.06; 1.1, 23.0, 63.2, 11.7, 0.3; 0.7]														
		Ketolide	Telithromycin	0.5	1.4	[0.8 - 2.2]	[Shaded area: 0.015-0.06; <0.1, 0.1, 8.0, 33.6, 38.4, 16.2, 1.8, 0.5; 1.4]													
			Macrolides	Azithromycin	0.0	1.5	[1.0 - 2.4]	[Shaded area: 0.015-0.06; 0.7, 16.8, 48.0, 26.7, 5.8, 0.4, <0.1; 1.5]												
		Erythromycin		0.0	1.5	[1.0 - 2.4]	[Shaded area: 0.015-0.06; 1.7, 25.2, 48.7, 18.7, 3.6, 0.4; 1.5]													
		Quinolones	Ciprofloxacin	0.0	23.0	[20.8 - 25.4]	[Shaded area: 0.015-0.06; 1.3, 29.2, 40.6, 4.9, 1.0, 0.1; 1.3, 9.4, 7.1, 3.3, 1.4, 0.4]													
Nalidixic acid	0.0		23.2	[21.0 - 25.5]	[Shaded area: 0.015-0.06; 64.1, 11.1, 1.6; 2.6, 20.6]															
II	Phenicol	Florfenicol††	0.0	0.6	[0.3 - 1.2]	[Shaded area: 0.015-0.06; <0.1, 14.8, 70.3, 12.2, 2.0, 0.5, <0.1]														
		Tetracyclines	Tetracycline	0.1	43.4	[40.7 - 46.1]	[Shaded area: 0.015-0.06; 4.6, 27.6, 16.3, 5.3, 2.1, 0.4, <0.1, 0.1, 0.4, 2.8, 10.6, 29.5]													
III	Lincosamides		Clindamycin	0.2	1.3	[0.8 - 2.1]	[Shaded area: 0.015-0.06; 1.5, 17.3, 45.4, 27.8, 5.0, 1.3, 0.1, 0.2, 0.3, 0.4, 0.7]													

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important; Rank 3, Important  
 † CLSI: Clinical and Laboratory Standards Institute  
 ‡ Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists  
 § Percent of isolates that were resistant  
 ¶ The 95% confidence intervals (CI) for percent resistant (%R) were calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method. The 95% CI is presented to summarize uncertainty in the observed resistance (R%).  
 \*\* The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the percentages of isolates with MICs equal to or less than the low est tested concentration. CLSI breakpoints were used when available.  
 †† Only a susceptible breakpoint (≤ 4 µg/ml) has been established. In this report, isolates with an MIC ≥ 8 µg/ml are categorized as resistant.

**Figure 26. Antimicrobial resistance pattern for *Campylobacter jejuni*, 2009**



**Table 50. Percentage and number of *Campylobacter jejuni* isolates resistant to antimicrobial agents, 2000–2009**

Year			2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total Isolates			306	365	329	303	320	791	709	992	1046	1355
Rank*	CLSI† Antimicrobial Class	Antibiotic (Resistance breakpoint)										
I	Aminoglycosides	Gentamicin (MIC ≥ 8)	0.0%	0.0%	0.0%	0.0%	0.3%	0.5%	0.0%	0.7%	1.1%	0.7%
		0	0	0	0	1	4	0	7	12	9	
	Ketolides	Telithromycin (MIC ≥ 16)	Not Tested	0.6%	0.8%	1.0%	2.2%	1.4%				
		5	6	10	23	19						
	Macrolides	Azithromycin (MIC ≥ 8)	1.6%	1.9%	1.8%	0.3%	0.6%	1.8%	0.8%	1.6%	2.3%	1.5%
		5	7	6	1	2	14	6	16	24	21	
Erythromycin (MIC ≥ 32)	1.0%	1.9%	1.2%	0.3%	0.3%	1.6%	0.8%	1.6%	2.3%	1.5%		
	3	7	4	1	1	13	6	16	24	21		
Quinolones	Ciprofloxacin (MIC ≥ 4)	14.7%	18.4%	20.7%	17.2%	18.1%	21.5%	19.5%	25.8%	22.4%	23.0%	
	45	67	68	52	58	170	138	256	234	312		
Nalidixic acid (MIC ≥ 64)	16.0%	18.9%	21.3%	17.8%	18.4%	21.9%	19.0%	26.1%	22.8%	23.2%		
	49	69	70	54	59	173	135	259	239	314		
II	Phenicol	Chloramphenicol (MIC ≥ 32)	0.0%	0.3%	0.3%	0.0%	1.6%	Not Tested				
		0	1	1	0	5						
		Florfenicol‡	Not Tested	0.5%	0.0%	0.0%	0.6%	0.6%				
Susceptible breakpoint: (MIC ≤ 4)	Tested	Tested	Tested	Tested	Tested	4	0	0	6	8		
	Tetracyclines	Tetracycline (MIC ≥ 16)	39.2%	40.3%	41.3%	38.3%	46.9%	41.8%	47.4%	44.8%	44.3%	43.4%
120	147	136	116	150	331	336	444	463	588			
III	Lincosamides	Clindamycin (MIC ≥ 8)	0.7%	1.9%	1.8%	0.0%	2.2%	1.1%	1.0%	1.3%	2.1%	1.3%
2	7	6	0	7	9	7	13	22	18			


\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important; Rank 3, Important  
 † CLSI: Clinical and Laboratory Standards Institute  
 ‡ Only a susceptible breakpoint (≤ 4 µg/ml) has been established. In this report, isolates with an MIC ≥ 8 µg/ml are categorized as resistant

**Table 51. Minimum inhibitory concentrations (MICs) and resistance of *Campylobacter coli* isolates to antimicrobial agents, 2009 (N=143)**

Rank*	CLSI† Antimicrobial Class	Antimicrobial Agent	% of isolates			Percent of all isolates with MIC (µg/mL)**														
			%‡	%R§	[95% CI]¶	0.015	0.03	0.06	0.125	0.25	0.50	1	2	4	8	16	32	64	128	256
I	Aminoglycosides	Gentamicin	0.0	2.8	[0.8 - 7.0]	[Shaded area from 0.06 to 2.8]														
		Ketolide	Telithromycin	4.9	2.1	[0.4 - 6.0]	[Shaded area from 0.06 to 2.1]													
	Macrolides	Azithromycin	0.0	2.8	[0.8 - 7.0]	[Shaded area from 0.06 to 2.8]														
		Erythromycin	0.0	2.8	[0.8 - 7.0]	[Shaded area from 0.06 to 2.8]														
	Quinolones	Ciprofloxacin	0.7	21.7	[15.2 - 29.3]	[Shaded area from 0.06 to 21.7]														
Nalidixic acid		0.7	23.1	[16.4 - 30.9]	[Shaded area from 0.06 to 23.1]															
II	Phenicol	Florfenicol††	0.0	0.0	[0.0 - 2.5]	[Shaded area from 0.06 to 0.0]														
		Tetracyclines	Tetracycline	0.0	44.8	[36.4 - 53.3]	[Shaded area from 0.06 to 44.8]													
III	Lincosamides	Clindamycin	1.4	2.1	[0.4 - 6.0]	[Shaded area from 0.06 to 2.1]														

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important; Rank 3, Important  
 † CLSI: Clinical and Laboratory Standards Institute  
 ‡ Percent of isolates with intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists  
 § Percent of isolates that were resistant  
 ¶ The 95% confidence intervals (CI) for percent resistant (%R) were calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method. The 95% CI is presented to summarize uncertainty in the observed resistance (R%).  
 \*\* The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the percentages of isolates with MICs equal to or less than the low est tested concentration. CLSI breakpoints were used when available.  
 †† Only a susceptible breakpoint (≤ 4 µg/ml) has been established. In this report, isolates with an MIC ≥ 8 µg/ml are categorized as resistant.

**Figure 27. Antimicrobial resistance pattern for *Campylobacter coli*, 2009**



**Table 52. Percentage and number of *Campylobacter coli* isolates resistant to antimicrobial agents, 2000–2009**

Year			2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
<b>Total Isolates</b>			<b>12</b>	<b>17</b>	<b>25</b>	<b>22</b>	<b>26</b>	<b>98</b>	<b>97</b>	<b>105</b>	<b>110</b>	<b>143</b>
Rank*	CLSI† Antimicrobial Class	Antibiotic (Resistance breakpoint)										
I	Aminoglycosides	Gentamicin (MIC ≥ 8)	8.3%	0.0%	0.0%	4.5%	0.0%	2.0%	1.0%	0.0%	0.9%	2.8%
			1	0	0	1	0	2	1	0	1	4
	Ketolides	Telithromycin (MIC ≥ 16)	Not Tested	4.1%	7.2%	5.7%	5.5%	2.1%				
								4	7	6	6	3
	Macrolides	Azithromycin (MIC ≥ 8)	8.3%	5.9%	4.0%	9.1%	0.0%	3.1%	8.2%	5.7%	10.0%	2.8%
			1	1	1	2	0	3	8	6	11	4
	Erythromycin (MIC ≥ 32)	8.3%	5.9%	4.0%	9.1%	0.0%	3.1%	8.2%	5.7%	10.0%	2.8%	
		1	1	1	2	0	3	8	6	11	4	
Quinolones	Ciprofloxacin (MIC ≥ 4)	25.0%	47.1%	12.0%	22.7%	30.8%	23.5%	21.6%	28.6%	30.0%	21.7%	
		3	8	3	5	8	23	21	30	33	31	
	Nalidixic acid (MIC ≥ 64)	25.0%	47.1%	12.0%	22.7%	34.6%	26.5%	23.7%	30.5%	30.0%	23.1%	
		3	8	3	5	9	26	23	32	33	33	
II	Phenicol	Chloramphenicol (MIC ≥ 32)	0.0%	0.0%	0.0%	0.0%	0.0%	Not Tested				
			0	0	0	0	0					
		Florfenicol‡ (Susceptible breakpoint: (MIC ≤ 4))	Not Tested	1.0%	0.0%	0.0%	0.0%	0.0%				
Tetracyclines	Tetracycline (MIC ≥ 16)	25.0%	58.8%	40.0%	45.5%	38.5%	30.6%	39.2%	41.9%	40.0%	44.8%	
		3	10	10	10	10	30	38	44	44	64	
III	Lincosamides	Clindamycin (MIC ≥ 8)	8.3%	5.9%	4.0%	9.1%	0.0%	4.1%	9.3%	5.7%	9.1%	2.1%
			1	1	1	2	0	4	9	6	10	3

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important; Rank 3, Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Only a susceptible breakpoint (≤ 4 µg/ml) has been established. In this report, isolates with an MIC ≥ 8 µg/ml are categorized as resistant

## References

CDC. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): 2005 Human Isolates Final Report. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2007.

Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria: Approved Guideline. CLSI Document M45-A2. CLSI, Wayne, Pennsylvania, 2010.

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI Document M100-S20-. CLSI, Wayne, Pennsylvania, 2010.

Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard-Eighth Edition. CLSI Document M07-A8. CLSI, Wayne, Pennsylvania, 2009.

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard-Third Edition. CLSI Document M31-A3. CLSI, Wayne, Pennsylvania, 2008.

Flleiss JL, Levin B, Paik MC. Statistical Methods in for Rates and Proportions. In: Shewart WA, Wilks SS, eds. Wiley Series in Probability and Statistics. Published Online; 2004.

Gonzalez, I, Grant KA, Richardson PT, Park SF, Collins MD. Specific identification of the enteropathogens *Campylobacter jejuni* and *Campylobacter coli* by using a PCR test based on the *ceuE* gene encoding a putative virulence determinant. *Journal of Clinical Microbiology* 1997;35:759-63.

Linton D, Lawson AJ, Owen RJ, Stanley J. PCR detection, identification to species level, and fingerprinting of *Campylobacter jejuni* and *Campylobacter coli* direct from diarrheic samples. *Journal of Clinical Microbiology* 1997;35:2568-72.

Linton D, Owen RJ, Stanley J. Rapid Identification by PCR of the genus *Campylobacter* and of five *Campylobacter* species enteropathogenic for man and animals. *Research in Microbiology* 1996;147:707-718.

Pruckler, J., et al., Comparison of four real-time PCR methods for the identification of the genus *Campylobacter* and speciation of *C. jejuni* and *C. coli*. ASM 106<sup>th</sup> General meeting; Poster C282.

World Health Organization (WHO). Critically Important Antimicrobials for Human Medicine. Report of the Second WHO Expert Meeting. Switzerland, 2007.

Folster JP, Rickert R, Barzilay EJ, Whichard JM. Identification of the aminoglycoside resistance determinants, *armA* and *rmtC* among non-Typhi *Salmonella* isolates from humans in the United States. *Antimicrob Agents Chemother*. 2009 Oct;53(10): 4563-4.

Hendricksen RS, Mikoleit M, Kornschöber C, Rickert RL, Van Duyne S, Kjelso C, Hasman H, Cormican M, Mevius D, Threlfall EJ, Angulo FJ. Emergence of multidrug-resistant *Salmonella* Concord infections in Europe and the United States in children adopted from Ethiopia, 2003-2007. *Pediatr Infect Dis J*. 2009 Sept;28(9):814-8.

Hendricksen RS, Seyfarth AM, Jensen AB, Whichard JM, Karlsmose S, Joyce K, Mikoleit M, DeLong SM, Weill FX, Aidara-Kane A, Lo Fo Wong DM, Angulo FJ, Wegener HC, Aarestrup FM. Results of use of WHO Global Salm-Surv external quality assurance system for antimicrobial susceptibility testing of *Salmonella* isolates from 2000-2007. *J Clin Microbiol*. 2009 Jan;47(1):79-85.

Lynch M, Blanton EM, Bulens S, Polyak C, Stevenson J, Medalla F, Barzilay E, Joyce K, Barrett T, Mintz ED. Typhoid fever in the United States, 1999-2006. *JAMA*. 2009 Aug;302(8): 859-65.

Petrov P, Hendricksen RS, Kantardjev T, Asseva G, Sorensen G, Fields P, Mikoleit M, Whichard JM, McQuiston JR, Torpdahi M, Aarestrup FM, Angulo FJ. Occurrence and characterization of *Salmonella enterica* subspecies *enterica* serovar 9,12:l,v:- strains from Bulgaria, Denmark, and the United States. *Eur J Clin Microbiol Infect Dis*. 2009

Sjölund-Karlsson M, Folster JP, Pecic G, Joyce K, Medalla F, Rickert R, Whichard JM. Emergence of plasmid-mediated quinolone resistance among non-Typhi *Salmonella enterica* isolates from humans in the United States. *Antimicrob Agents Chemother*. 2009 May; 53(5):2142-4.

## Appendix A

### Summary of *Escherichia coli* Resistance Surveillance Pilot Study, 2009

#### ***Escherichia coli* working group**

#### **Centers for Disease Control and Prevention**

Frederick Angulo, Ezra Barzilay, Patricia Griffin, Amy Krueger, Rebecca Howie, Kathryn Lupoli, Andre McCullough, Kevin Joyce, Felicita Medalla  
Foodborne and Diarrheal Diseases Branch, Division of Bacterial and Mycotic Diseases  
National Center for Infectious Diseases

#### ***Michigan Department of Community Health and William Beaumont Hospital***

Sue Donabedian, Mary Beth Perry, Mary Thill, Mark Zervos

## INTRODUCTION

*Escherichia coli* is a Gram–negative coccobacillus bacterium that is part of the intestinal flora of humans and other animals. Because antimicrobial resistance genes commonly reside in mobile genetic elements that can be transferred horizontally to other bacteria, antimicrobial–resistant bacteria of the intestinal flora, including *E. coli*, constitute an important reservoir of resistance genes for pathogenic bacteria of humans and other animals. Furthermore, when introduced into a normally sterile site, *E. coli* is an important cause of infections, including septicemia, urinary tract infections, and wound infections. The human intestinal tract is the predominant source of *E. coli* causing these infections. Antimicrobial resistance among *E. coli* causing such infections complicates treatment options.

The use of antimicrobial agents creates a selective pressure for the emergence and dissemination of resistant bacteria. Use of antimicrobial agents in food animals selects resistant bacteria, including resistant *E. coli* in the intestinal tract of food animals. These resistant bacteria can be transmitted to humans through the food supply. Therefore, monitoring resistance in *E. coli* isolated from the intestinal flora of humans and animals is important to determining the role of these bacteria as human pathogens and as reservoirs of resistance determinants for human pathogens. The *E. coli* Resistance Surveillance Pilot is designed to determine the prevalence of resistance to clinically important antimicrobial agents among *E. coli* isolated from persons in the community.

## SUMMARY OF 2009 SURVEILLANCE DATA

### Background

Beginning in 2004, NARMS began to prospectively monitor the prevalence of antimicrobial resistance of *E. coli* isolated from human stool samples in two sites: Maryland and Michigan.

## SURVEILLANCE AND LABORATORY TESTING METHODS

In 2009, Michigan was the sole participant in the study. Michigan cultured 10 human stool samples, from outpatients, each month for *E. coli* using Eosin Methylene Blue agar and subsequent biochemical confirmation. One *E. coli* isolate, if present, from each stool sample was sent to CDC for susceptibility testing to antimicrobial agents using broth microdilution (Sensititre<sup>®</sup>) to determine the minimum inhibitory concentration (MIC) for each of

15 antimicrobial agents: amikacin, ampicillin, amoxicillin-clavulanic acid, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfonamides, tetracycline, and trimethoprim-sulfamethoxazole.

Interpretive criteria from the Clinical and Laboratory Standards Institute (CLSI) were used when available ([Table 53](#)). The 95% CIs for the percentage of resistant isolates calculated using the Clopper-Pearson exact method, are included in the MIC distribution tables. Similarly, multiclass resistance by CLSI antimicrobial class was defined as resistance to two or more classes.

## RESULTS

In 2009, CDC received 45 isolates; of these, 45 (100.0%) were viable *E. coli* isolates. MIC was determined for *E. coli* isolates for 15 antimicrobial agents ([Table 54](#)). Of the 45 *E. coli* isolates, 22.2% (10/45) were resistant to ampicillin, 17.8% (8/45) to sulfisoxazole, 17.8% (8/45) to tetracycline, and 8.9% (4/45) to nalidixic acid ([Table 55](#)).

### Multidrug-Resistant *E. coli*

Multidrug resistance is described in NARMS by the number of antimicrobial classes and also by specific coresistant phenotypes. Antimicrobial classes of agents defined by CLSI are used in this report.

- 11.1% (5/45) of *E. coli* isolates were resistant to three or more classes of antimicrobial agents ([Table 56](#)).
- 8.9% (4/45) of *E. coli* isolates were resistant to five or more classes of antimicrobial agents ([Table 56](#)).

### Clinically Important Resistance

Antimicrobial agents commonly used to treat serious *E. coli* infections in humans include third-generation cephalosporins and fluoroquinolones.


- 2.2% (1/45) of *E. coli* isolates were resistant to ceftriaxone ([Table 55](#)).
- 8.9% (4/45) of *E. coli* isolates were resistant to ciprofloxacin ([Table 55](#)).

## REFERENCES

1. Levy SB, Fitzgerald GB, Macone AB. Changes in intestinal flora of farm personnel after introduction of a tetracycline-supplemented feed on a farm. *The New England Journal of Medicine* 1976;295:583–8.
2. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. *The American Journal of Medicine* 1991;91(Suppl 3B):3B-72S–5S.
3. Van den Bogaard AE, Stobberingh EE. Epidemiology of resistance to antibiotics: links between animals and humans. *International Journal of Antimicrobial Agents* 2000;14:327–35.
4. Corpet DE. Antibiotic resistance from food. *The New England Journal of Medicine* 1988;318:1206–7.
5. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI Document M100-S20. CLSI, Wayne, Pennsylvania, 2010.



**Figure 28. Antibiotic resistance pattern for *Escherichia coli*, 2009**



**Table 55. Percentage and number of *Escherichia coli* isolates resistant to antimicrobial agents, 2004–2009**

Year			2004	2005	2006	2007	2008	2009
Total Isolates			151	119	82	66	57	45
Rank*	CLSI† Antimicrobial Class	Antibiotic (Resistance breakpoint)						
I	Aminoglycosides	Amikacin (MIC ≥ 64)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
		Gentamicin (MIC ≥ 16)	2.0%	3.4%	3.7%	3.0%	0.0%	0.0%
		Streptomycin (MIC ≥ 64)	10.6%	14.3%	7.3%	13.6%	8.8%	8.9%
	β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid (MIC ≥ 32)	2.6%	4.2%	3.7%	0.0%	3.5%	2.2%
		Cephems						
	Cephems	Cefiofur (MIC ≥ 8)	0.0%	0.8%	0.0%	0.0%	1.8%	2.2%
		Ceftriaxone (MIC ≥ 64)	0.0%	0.8%	0.0%	0.0%	1.8%	2.2%
	Penicillins	Ampicillin (MIC ≥ 32)	24.5%	26.1%	28.0%	21.2%	26.3%	22.2%
	Quinolones	Ciprofloxacin (MIC ≥ 4)	3.3%	7.6%	4.9%	7.6%	10.5%	8.9%
		Nalidixic Acid (MIC ≥ 32)	9.3%	9.2%	11.0%	10.6%	12.3%	8.9%
II	Aminoglycosides	Kanamycin (MIC ≥ 64)	2.0%	0.0%	0.0%	1.5%	1.8%	6.7%
		Cephems						
	Folate pathway inhibitors	Cefoxitin (MIC ≥ 32)	2.6%	0.8%	1.2%	0.0%	0.0%	6.7%
		Sulfisoxazole‡ (MIC ≥ 512)	17.9%	18.4%	17.1%	24.2%	14.0%	17.8%
	Phenicols	Trimethoprim-sulfamethoxazole (MIC ≥ 4)	11.3%	14.9%	12.2%	15.2%	12.3%	8.9%
		Chloramphenicol (MIC ≥ 32)	1.3%	2.5%	3.7%	3.0%	5.3%	2.2%
Tetracyclines	Tetracycline (MIC ≥ 16)	13.2%	19.3%	14.6%	21.2%	14.0%	17.8%	

\* Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I): Rank 1, Critically Important; Rank 2, Highly Important

† CLSI: Clinical and Laboratory Standards Institute

‡ Results unavailable for 5 isolates

**Table 56. Resistance patterns of *Escherichia coli* isolates, 2004–2009**

Year	2004	2005	2006	2007	2008	2009
<b>Total Isolates</b>	<b>151</b>	<b>119</b>	<b>82</b>	<b>66</b>	<b>57</b>	<b>45</b>
	%	%	%	%	%	%
	n	n	n	n	n	n
No resistance detected	62.9%	63.0%	63.4%	65.2%	64.9%	68.9%
	95	75	52	43	37	31
Resistance ≥1 CLSI class*	37.7%	37.0%	36.6%	34.8%	35.1%	31.1%
	57	44	30	23	20	14
Resistance ≥2 CLSI classes*	17.9%	22.7%	22.0%	21.2%	21.1%	13.3%
	27	27	18	14	12	6
Resistance ≥3 CLSI classes*	9.9%	14.3%	15.9%	15.2%	12.3%	11.1%
	15	17	13	10	7	5
Resistance ≥4 CLSI classes*	5.3%	9.2%	8.5%	9.1%	8.8%	8.9%
	8	11	7	6	5	4
Resistance ≥5 CLSI classes*	3.3%	7.6%	1.2%	4.5%	7.0%	8.9%
	5	9	1	3	4	4
At least ACSSuT <sup>†</sup>	1.3%	0.8%	0.0%	0.0%	1.8%	0.0%
	2	1	0	0	1	0
At least ACT/S <sup>‡</sup>	1.3%	0.8%	1.2%	1.5%	3.5%	0.0%
	2	1	1	1	2	0
At least ACSSuTAuCx <sup>§</sup>	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	0	0	0	0	0	0
At least ceftriaxone and nalidixic acid resistant	0.0%	0.0%	0.0%	0.0%	1.8%	2.2%
	0	0	0	0	1	1

\* CLSI: Clinical and Laboratory Standards Institute

† ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline

‡ ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole

§ ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone